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7General abstract
Introduction
In an economic evaluation, we estimated the cost-effectiveness of sildenafil (Viagra) in
terms of costs per quality adjusted life year (QALY).
Methods
A sample of 169 subjects of the general public and 106 patients valued question 3 and 4
of the International Index of Erectile Function (IIEF) in terms of Time Trade-Off (TTO).
These questions were used as the primary outcome measures in the Viagra trial of
Goldstein et al. (1998) to establish the efficacy of Viagra. Using the TTO-values, we
could recalculate the trial results into QALYs. Costs were estimated from the societal
perspective. We compared the cost-effectiveness of Viagra with Androskat, an
intracavernosal injection therapy for erectile dysfunction, which is reimbursed in The
Netherlands. Because the effects of Androskat on the IIEF are unknown, it was assumed
that the effect size was valued the same as Viagra, which is a conservative assumption.
Results
The cost price per QALY was NLG 13227.36 for Viagra and NLG 15745.55 for
Androskat in the first year and NLG 8261.36 for Viagra and NLG 7587.82 for Androskat
in each following year. The incremental cost-effectiveness ratio for Viagra as compared
to Androskat was NLG 9750.80 for the first year and NLG 9098.52 for each following
year.
Discussion
The relatively low cost-effectiveness ratio of Viagra suggests that this is a cost-effective
medicine.
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1. Introduction
1.1. Erectile dysfunction and Viagra®
On 15 September 1998 the European Agency for the Evaluation of Medicinal Products
authorised the release of Viagra (sildenafil) in the European Union.1 At the time of the
authorisation of the release, the cost-effectiveness of Viagra was still unknown. This
complicates decisions about a possible reimbursement, as the cost-effectiveness is seen
as an important argument is this political decision. For this reason Pfizer BV, the
marketing Authorisation Holder responsible for Viagra in the Netherlands, invited the
institute for Medical Technology Assessment (iMTA) to perform a pharmaco-economic
evaluation of Viagra, in order to estimate the cost-effectiveness of Viagra. This document
is the report of the investigation of iMTA.
The active substance of Viagra is sildenafil. Sildenafil is indicated for the treatment of
erectile dysfunction, which is the inability to attain and/or maintain a penile erection
sufficient for satisfactory sexual performance.2 Sildenafil is the first effective and
tolerable oral therapy which is available in the Netherlands for the treatment of erectile
dysfunction. Sildenafil is an inhibitor of cyclic guanosine monophosphate (cGMP)
specific phosphodiesterase (PDE5). PDE5 is the predominant enzyme responsible for
the degradation of cGMP in the corpus cavernosum. During a natural erection cGMP is
triggered by the release of nitric oxide. In turn, cGMP is responsible for relaxation of the
corpus cavernosum, which increases the blood flow to the penis and builds up
intracavernosal pressure and penile erection.3
The extent of erectile dysfunction as a health problem is difficult to assess. Patients are
ashamed for their erectile dysfunction, hence a lot of patients do not seek treatment.4 It
is expected that greater numbers of patients will seek treatment in the future, as
awareness of the disorder and of successful non-invasive treatment like Viagra grows.
Nevertheless, until now the prevalence and incidence of erectile dysfunction are still dark
numbers. Estimates for the incidence and prevalence can be derived from the
Massachusetts Male Aging Study.5 The results of this study confirmed that the
prevalence of erectile dysfunction is associated with age. Between the ages  40 to 70,
the prevalence of complete erectile dysfunction tripled from 5 to 15%, while the
probability of moderate impotence doubled from 17  to 34%.
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Concepts about the etiology of erectile dysfunction have changed during the last
decade. Until the 1970s, erectile dysfunction was regarded primary as a psychogenic
disorder. Nowadays it is argued that the origin of most erectile dysfunction is
multifactorial. It is now believed that most erectile dysfunction originates from organic
causes (mostly neurological and vascular problems), though an emotional component is
common, especially in younger men.6
1.2. Alternative therapies
Besides Viagra there are several other medical interventions available for the treatment
of erectile dysfunction. Possible alternatives are other oral agents, psychotherapy or
behavioural therapy, vascular surgery, intracavernosal injections, vacuum constriction
devices and prosthesis.2 Only the last three therapies are assumed to be acceptable.7
The others have low effect and/or low tolerability (f.i. Yohimbine, an oral agent or
vascular surgery (recurrence of the problem)), which is in most cases also not
adequately documented.2 Psychotherapy is indicated for erectile dysfunction of
psychologic origin or as adjunct to other therapies, however outcome data are also not
well-documented.2 Below we will describe the three acceptable therapies.
Intracavernosal injections (IC-injections) are injections of a vasoactive substance into the
corpus cavernosum, which cause the muscles in the corpus cavernosum to relax.
Various studies of IC-injections have demonstrated high initial success rates for
producing erections. IC-injections have success rates of 60 to 70% for patients who have
vasculogenic erection dysfunction, and 100% for patients with erectile dysfunction from
neurogenic origin.6 IC-injections are the most effective therapy in terms of rigid
erections. However, despite the high efficacy for producing erections, studies have
demonstrated generally low levels of patient/partner satisfaction, low levels of patient
preference for IC-injections and high drop-out rates. Thirty to sixty percent of the patients
who start with IC-injection therapy do not continue or report that they are not satisfied
with the therapy.8, 9, 10 In the Netherlands alprostadil (Caverject®) and the combination
of papaverine and phentolamine (Androskat®) are authorised for the treatment of erectile
dysfunction. There are some differences in effectiveness, though it is not possible to
predict in advance which patients will profit most from which treatment. Only IC-
injections with Androskat are reimbursed through the social health insurance system.
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Vacuum constriction therapy can produce erections in every patient. They consist of a
closed plastic cylinder fitted over the penis from which air is drawn with either a manual
or battery powered pump in order to create a vacuum and cause the corpora to fill with
blood. A tension band is applied at the basis of the penis to ensure the erection is
maintained. These are highly efficacious devices. Complications include a cold penis
and occasional petechiae associated with too great negative pressure. The rigidity of the
erection is not always sufficient for sexual intercourse at the basis of the penis.6, 11
Another acceptable treatment is the penile prosthesis implantation.7 Potential
complications are infections, erosion and mechanical failure. Prosthesis are seen as the
last resort because of irreversible damage.6, 8
Viagra has the potential to become the new treatment of choice for erectile dysfunction,
given the good efficacy and the relative mild side effects. The overall clinical safety of
oral sildenafil was evaluated in more than 3700 patients.3 Long-term sildenafil treatment
(up to 1 year) was received by 2199 patients. The most commonly adverse events were
headache (16% sildenafil, 4% placebo), flushing (10% sildenafil, 1% placebo) and
dyspepsia (7% sildenafil, 2% placebo) and they were predominantly transient and mild or
moderate in nature. The rate of discontinuation due to adverse events was comparable
in patients and placebo, respectively 2,5% and 2,3%.
1.3. Research questions
Although Viagra has the potential to become the new treatment of choice for erectile
dysfunction, whether or not Viagra is reimbursed is a political decision. The decision is
political because the resources available for health care are limited and therefore the
reimbursement of a new therapy has to be compared to all other possible allocations. An
important argument in such deliberation is the magnitude of the effects compared to the
costs of the different interventions. In other words, to convince health authorities that
Viagra should be reimbursed through the social health insurance system, it would be
necessary to show the relative cost-effectiveness of Viagra in comparison to other health
care interventions in general and other treatment strategies for erectile dysfunction in
particular. The present investigation is initiated to determine the costs and effects of
Viagra. Thus the main research question can be formulated as follows: What is the cost-
effectiveness of Viagra?
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In line with the intention to compare the cost-effectiveness of Viagra with other possible
health care interventions, the economic evaluation of Viagra is performed form a societal
perspective. This societal perspective is the preferred perspective in health
economics.12 This perspective prescribes that all costs and effects must be measured,
no matter who bears these costs or who receives the effects. With respect to the costs in
the health care sector, a complete overview of costs in the different sectors is necessary
in order to give insight into possible substitution effects. With respect to the effects, the
societal perspective demands that the health effects should be valued by the general
public.13 This is in line with the “insurance principle” which dominates the financing
structure of most health care systems.14
In contrast to the estimation of the effects, the estimation of the costs is relatively
straightforward. The challenge of the investigation is the valuation of the effects from a
societal perspective. The effects of Viagra have to be valued in such a way that
comparisons with the benefits of other interventions in health care can be made.
Normally the values or the “utilities” of the effects of a therapy are measured alongside a
clinical trial. During the clinical trial, generic quality of life questionnaires are given to the
patients, like the EuroQol or the Health Utility Index. These questionnaires classify the
patients in so called “health states”. The values of the general public for these health
states have already been determined in large scale investigations in the general public.
Unfortunately, these questionnaires have not been used in the Viagra trials. And even if
one had included them in the trials, one could have doubts about the sensitivity of these
questionnaires for problems related to erectile dysfunction. Instead, the outcomes of the
Viagra trials were determined in terms of a disease specific questionnaire.15 In this
investigation, the challenge was to re-examine and modify the disease specific outcomes
in such a way that they now give scores in term of values (utilities) which can be used in
economic appraisal. This strategy is advised by Brazier et al.16 However, to our
knowledge we are the first to apply this strategy. Therefore we examined the feasibility
and validity of this strategy. The first additional research question formulated is therefore:
Is it possible to value the outcomes of a disease specific questionnaire of quality of life
into utilities in a valid way?
A major drawback in the assessments of the benefit of health care by the general public
is that they lack the experiences of patients. In the societal perspective, the values of the
general public are only valid when the respondents are “well-informed”.13 This may
especially be a problem when the general public is not exposed to the disease. Erectile
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dysfunction may be such a disease, given the hidden suffering of the patients. Thus, the
public may be unaware of the decrease in quality of life due to erectile dysfunction.
When one can doubt the awareness within the general public, it may be informative to
compare the values of the general public with values given by the patients. These
patients’ values also have a meaning on their own: they represent the values from a
“patient perspective”, also called the “clinical perspective”. Outcomes from the patient
perspective are informative to maximise the benefits in a patient population, which
support medical decisions when costs are not an issue. When costs are an issue, the
use of patients’ values is dissuaded.14 Nevertheless, these values can be used to get an
indication of the validity of values of the general public. This is translated into the second
additional research question: To what extent differ values given by patients and the
general public for health states associated with erectile dysfunction?
We further anticipated that personal circumstances (such as having a partner) and
personal characteristics (such as age, gender and the subjective enjoyment of sex)
would moderate the impact of erectile dysfunction on quality of life considerable. This
may not only be true for patients with erectile dysfunction, but also for the general public,
when they value the effects of medical interventions which could improve erectile
functioning. If the differences are substantial and meaningful from a policy perspective, it
is advised to consider different cost-effectiveness analysis for these subgroups.13, page
102 For this reason we formulated the last additional research question: What are the
systematic relations between the values for erectile dysfunction and the background
variables in the general public?
1.4. Structure of this report
Chapter 2, 3, and 4 address the main question of our investigation: the economic
appraisal of Viagra. Chapter 2 accounts for the methodology. This chapter describes the
study design, the treatment comparator and the analytical techniques we used. Chapter
3 presents the results of the economic evaluation. The presentation of the results
consists of a presentation of all compounds of the estimation of the costs and effects
separately, and of the outcomes aggregated into a cost per QALY. Chapter 4 contains
the discussion of the results, the conclusions and the considering of the limitations of the
study.
15
The first two appendices present details about the three additional research questions of
this study: Appendix A, “Converting clinical outcomes into utilities: the valuation of
International Index of Erectile Function (IIEF)” reports about the validation of the erectile
dysfunction states. Appendix B, “Differences in the values given by the general public
and patients to health states of erectile dysfunction” describes the influences of the
background variables and the influence of the perspective: how are the values of
patients related to the values of the general public. Finally, appendix C provides an
overview of all persons who where involved in this study and their contribution.
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2. Methods
2.1. Study design
This study is performed from the societal perspective. This means that all costs are
relevant no matter who is paying them.1 Furthermore, the societal perspective demands
that the health effects should be valued by the general public.2 In order to meet these
criteria, we tried to estimate all costs associated with the use of Viagra. Furthermore, we
used values or “utilities” of the general public to value the established clinical effect of
Viagra. The data regarding the clinical effect of Viagra were derived from the clinical trial
described by Goldstein et al.3 After weighing the clinical effects with the values of the
general public, we converted the effects to Quality Adjusted Life Years, the preferred
outcome measure in health economics.1, 2 The methods we used to estimate the costs
and effects are described below.
2.2. Effects
Goldstein, Lue, Padma-Nathan et al. (1998) evaluated the efficacy of Viagra in two
clinical trials; one dose-response study and one dose-escalation study. A full report of
these clinical trials is published in the New England Journal of Medicine (vol. 338, issue
20, page 1397-1404). We used the data of the dose-escalation study to determine the
effect of Viagra from a societal perspective. We chose this study for two reasons. In the
first place because it is one of the largest clinical trials of Viagra that has been reported,
and the one with the longest follow-up so far. Secondly, because future patients will try
to find the most suitable dosage, the dose escalation study provides best insight in the
usage of Viagra in practice.
The dose-escalation study performed by Goldstein et al. consisted of 329 men who were
treated with placebo or Viagra. Depending on the dose, side effects occurred in 6 to 18%
of the men, but only 2% withdrew because of treatment-related adverse effects. The
mean numbers of successful intercourse attempts were 5.9 for the men receiving Viagra
and 1.5 for those receiving placebo. The efficacy was assessed with the International
Index of Erectile Function (IIEF). This is a disease specific questionnaire to quantify the
degree of erectile dysfunction, which includes quality of life aspects. Two question of the
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IIEF were use as primary endpoint in the assessment of the efficacy of Viagra: question
3 and 4 (Table 1).
Table 1: Question 3, 4 of the International Index of Erectile Function (IIEF)
IIEF Question 3 IIEF Question 4 Response level
During the past 4 weeks,
how often were you able to
penetrate?
During the past 4 weeks,
how often were you able to
maintain the erection?
Almost never or never Almost never or never 1
A few times A few times 2
Sometimes Sometimes 3
Most times Most times 4
Almost always or always Almost always or always 5
Converting the clinical effects of treatment with Viagra into utilities
Our estimation of the utilities gained by Viagra treatment, is based on the effectiveness
of Viagra in the clinical trial described above. We calculated the mean utility gained for
the patients in the trial. To that end, we attribute utilities to the 25 health states that can
be defined using questions 3 and 4 of the IIEF. These utilities were collected in a
separate investigation in which a representative sample of the general public valued the
25 health states. Hundred and sixty nine subjects form the general public valued the 25
health states as defined IIEF with time trade-off. Time trade-off is one of the preferred
valuation methods in health economics that are used to determine the values or “utilities”
of health states.1 The results of this study support the validity of the process of valuing
the outcomes of disease specific questionnaires into utilities. This investigation is
described in detail in appendix A.
Because it is possible that the awareness in the general public for erectile dysfunction is
low and because of the subjective nature of the enjoyment of sex, we also collected
patients’ values for the different health states of erectile dysfunction. We did this in the
same way as we collected values from the general public. For this purpose the 25 health
states of as defined by question 3 and 4 of the IIEF were valued by 106 patients who
participated in a phase 4 trial of Viagra. This investigation is described in detail in
appendix B. In a sensitivity analysis we investigated how the cost-effectiveness ratio is
affected by the use of different values.
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Besides making differences between patient values and values for the general public,
one can also look at the possibility that subgroups within the patients or within the
general public have different values. If the differences are substantial and meaningful
from a policy perspective, Gold, Patrick & Torrance et al. (1996, page 102) advise to
consider different cost-effectiveness analyses for these subgroups. In appendix B we
investigated the influence of background variables like age, gender, availability of a
partner, having children, sexual activity and sexual satisfaction.
Calculating QALYs
We attributed the utilities of the general public to the health states of the individual
patient, both before and after treatment. The difference between the mean utility before
and after treatment is the mean gain of utility. This effect is compared with the effect in
the placebo group and the differences between these two is used as the adjustment
factor for the calculation of the final effect parameter, namely Quality Adjusted Life Years
(QALYs). In a QALY analysis the remaining life years of an individual are adjusted for
the quality of life during this period. In this way a QALY combines the two most important
measures in health care: lifetime and quality of life. QALYs are the preferred effect
parameter in health economics, as it makes the effects of different allocations in health
care comparable.1, 2
2.3. Costs
Cost identification
In the societal perspective direct costs must be considered both inside and outside the
health care sector. Also indirect costs could be recognised.4 Below we describe these
considerations for the economic appraisal of Viagra.
Direct medical costs: within the health care sector
In an economic evaluation of a health care program an analysis of the direct
medical costs is always necessary.5 These direct medical costs are specific
to the therapy being investigated, and concern the resources used by a
20
health care program and consist of the costs of organising and operating the
program.
Direct non-medical costs: patient and family resources
The treatment of erectile dysfunction involves patients’ costs related to visits
to a general practitioner and to the pharmacy. Both are normally within a few
miles distance from the patients’ homes, hence the direct non-medical costs
are assumed to be negligible.
Indirect medical costs: within the health care sector
There is a low level of agreement whether these costs should be
incorporated in economic analysis.6, 7 However, in our study these costs play
no role anyway: because erectile dysfunction is not a life threatening
condition, it can be assumed that treatment of erectile dysfunction would not
save any life years. Therefore treating erectile dysfunction would not yield
additional medical costs in additional live years.
Indirect non-medical costs: sectors outside the health care system
Analyses of indirect non-medical costs are mostly focuses on costs of
production losses. Because patients with erectile dysfunction are in most
cases capable of performing their daily activities normally, the indirect non-
medical cost are not of relevance either.
In sum, it can be concluded that in the cost price calculation of treatment for erectile
dysfunction only the direct medical costs are of relevance. Estimating these costs,
means measurement of the quantities of resource use and the assignment of unit cost
prices to these resources. Both will be presented separately, in order to make the cost-
price calculation as transparent as possible.
The cost model
Given the many elements that are usually involved in a cost price calculation,
economists present their calculation in a cost model. Because such models are based
on many elements, the model structure is usually presented in the result section of the
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report. We will use this same lay out and present the details of the model along with the
results in the next chapter. Below we only describe the basic elements of the cost model.
Treatment regime
Treatment for erectile dysfunction starts with a period in which the right dosage for a
patient must be established. For a part of the patients the outcome is that the treatment
has no effect or has to many side effects. After establishing the right dosage for patients
who can be treated successfully, the costs remain constant. For that reason we calculate
separately the costs of the first year (in which the costs of non-successfully treated
patients are added to the costs of successfully treated patients) and the costs of each
year in which therapy is continued.
Treatment comparator
To make the results applicable to the Dutch health care setting, we chose to compare
the costs and effects of Viagra with the costs and effects of Androskat, a drug for erectile
dysfunction that is reimbursed through the social health insurance system.8 Androskat is
indicated for the treatment of erectile dysfunction. It involves injection of the active
substances papaverine and phentolamine in the corpus cavernosum of the penis. This
causes relaxation of the muscles in the corpus cavernosum, and subsequently an
erection. Side effects could be prolonged erections (4-5 hours), pain and fibrosis. The
maximum number of injections is limited to 1 per week because of these side effects.
The estimation of the cost and effects of Androskat
We compare Viagra and Androskat with respect to both costs and effects. The
estimation of costs of Androskat is based on the same assumption that only direct
medical costs are of importance. The effects of Androskat were not measured with the
IIEF, and no other investigations are reported which could be used to estimate the
number of QALYs gained as a result of the use of Androskat. Therefore we assume that
the utility gained by a patient who is successfully treated with Viagra is similar to the
utility gain of a patient who is successfully treated with Androskat. Given the obvious
differences in treatment and effects, this is a conservative assumption in the economic
appraisal of Viagra as compared to Androskat.
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Difference in effectiveness between Viagra and Androskat
The different treatment effects of Viagra and Androskat become evident when one
compares the effectiveness. An important difference between Viagra and Androskat is
that for 30% of the patients with erectile dysfunction only oral therapy is acceptable.9 For
these patients the enjoyment of sex is decreased with injection therapy (or the use of
vacuum devices), because this decreases the spontaneity of intercourse. This means
that effectiveness of Androskat and Viagra not only depends on the opportunity to create
an erection, but also on the acceptance of treatment. On the other hand, if Viagra yields
no response, some patients will start to use Androskat. We control for this effect in our
estimation of the costs and effects of both therapies.
The rationing of the treatment
In our comparison of the costs and effects we also have to deal with the fact that the use
of Androskat is rationed for medical reasons: too many erections can cause fibrosis in
the penis. To enhance the comparability of the use of Androskat and Viagra, we
compared both alternatives assuming the same frequencies of intercourse. However, the
use of Viagra is not rationed for medical reasons; the maximum recommended dosing
frequency is once a day. In the sensitivity analysis we will analyse how changes in
frequency of intercourse with Viagra would influence the cost. In this context it should be
noted that treatment of erectile dysfunction is valued as a relative increase of successful
attempts of intercourse and not as an absolute increase in the frequency of intercourse.
This means that we can not control for rationing the treatment in our effect analysis.
However, to use the same values for Viagra in Androskat is a conservative approach
with respect to the differences in costs and effects between Viagra and Androskat.
2.4. Cost-effectiveness
The results will first be presented in costs per QALY for patients in the Viagra scenario
Viagra and for patients in the Androskat scenario separately as compared to no
treatment. Because Androskat is an alternative for Viagra and is currently being
reimbursed, we will also present the results in the form of an incremental analysis: i.e. as
the differences in the costs and effects between Viagra and Androskat. This is relevant
because it is expected that Viagra will yield additional costs and additional effects,
because a larger population of patients with erectile dysfunction will seek treatment.
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2.5. Discounting
Because there is no time preference in treatment for erectile dysfunction (both costs and
effects are received at the same time) discounting of future costs is not necessary.
2.6. Time of the data collection
The collection of data concerning the costs and effects of Viagra and Androskat, was
done in the period between April 1998 and April 1999.
2.7. Sensitivity analysis
We performed a sensitivity analysis to estimate the effect of uncertainty regarding
different variables on the costs and effects. As indicated before, we will estimate how
changing the frequency of the use of Viagra affects the costs. Furthermore, we will
analyse how the use of different values influences the effects. However, the most
important goal of our sensitivity analysis is to deal with the uncertainties regarding the
quantities of resource use. This element of the sensitivity analysis is described below.
To calculate the costs and effects of Viagra we made a global estimate about the
quantities and cost prices of resource use. This estimation is based on data regarding
resource use in two different hospitals and on the suggested protocol for the treatment of
erectile dysfunction, which has been developed in a round table conference about
diagnosing and treating erectile dysfunction.10 It can be assumed that the protocol is
quite cautious in the sense that it prescribes more visits than will be made in daily
practice. Furthermore, daily practice appears to be different in different institutions. In
order to deal with the uncertainties regarding the quantities of resource use, we
modelled the costs into three scenarios, representing a high estimation of the costs, a
low estimation of the costs and a ‘base’ scenario, which includes our global estimate of
the costs. All three scenarios will be presented in our estimation of resource use in the
next chapter. The final estimation of cost-effectiveness of Viagra will be based on the
base scenario; the sensitivity analysis will indicate how the different scenarios would
affect the conclusions of our economic appraisal.
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3. Results
This chapter presents the cost-utility analysis of Viagra. The effects of treatment with
Viagra and of treatment with Androskat injections are reviewed in relation to the costs of
treatment. The results of the valuation of the IIEF, the first additional research question
are discussed in detail in appendix A. This chapter only presents the main outcomes of
that investigation. The same applies for the values of the patients and the influences of
the background variables on the values given by the general public. These results are
discussed in detail in appendix B.
3.1. Effects
The estimation of the effect size of Viagra is based on the changes reported on the IIEF
in the Viagra trial described by Goldstein, Lue, Padma-Nathan et al.1 In the article only
accumulated data are printed. We could not use these accumulated data, because for
the calculation of the cost-utility, we cannot assume that this 5 level scale of item 3 and 4
of the IIEF has interval properties. Table 1 therefore describes the same data in non-
accumulated form. For purpose of illustration, we printed in the same table the self-
reported erectile dysfunction in our sample of men of the general public. Note that the
figures in Table 1 only represent the men who had attempted intercourse in the 4 weeks
prior to the IIEF administration.
A sample of 169 subjects of the general public valued the 25 possible health states of
the IIEF with the use of time trade-off, the preferred valuation method in health
economics. As described in detail in appendix A, the estimated values of “utilities” of the
general public showed good content validity: the values were in the expected range and
consistent with the ordinal structure of the health states. There were differences
observed between some values of the group administration and the values of the
individual administration, but there was no overall effect. Next to the sample of the
general public, we also collected the patients’ values for the 25 health states of the IIEF,
in 106 patients. Appendix B describes that the patients’ values were found to be higher
than the values of the general public. The extent to which the mode of administration
influences our results is analysed in the sensitivity analysis, as is the difference between
patient values and the values of the general public.
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Table 1:Frequency distribution over de different ED-states
Sildenafil group (N=163) Placebo group (N= 166) General public
IIEF question 3 IIEF question 4 At baseline End-of-treatment At baseline End-of-treatment (N=78)
never Never 49 19 36 45 2
A few times 9 4 20 19 0
Sometimes 5 0 9 5 1
Most times 4 2 2 1 0
Always 4 1 1 2 0
a few times Never 0 0 1 1 0
A few times 7 4 9 13 0
Sometimes 5 4 2 5 0
Most times 5 2 3 4 1
Always 0 0 2 1 0
Sometimes Never 0 0 1 0 0
A few times 2 0 1 1 0
Sometimes 13 5 11 4 1
Most times 2 4 7 2 0
Always 2 4 2 1 1
most times Never 0 0 0 0 0
A few times 1 0 0 0 1
Sometimes 2 2 2 1 2
Most times 2 11 2 4 3
Always 1 9 5 7 1
Always Never 0 0 0 0 0
A few times 0 1 2 0 0
Sometimes 0 1 0 0 0
Most times 1 6 0 1 1
Always 2 55 2 9 44
Total 116 134 120 126 58
In the general public, all but one of the background variables showed no statistical
significant relation with the values given to health states of erectile dysfunction. The
exception was that subjects with children gave higher values to the health states. In
other words: subjects with children considered erectile dysfunction less of a problem
than subjects without children did.
The utilities attributed to the different states of erectile dysfunction by the general public
are presented in Table 2. There is no value elicited for normal erectile function, because
this health states (normal health) is used as a reference point in time trade-off. The value
for this state is set at 1.00.
Table 2: Values of the general public for erectile dysfunction (N=148)
IIEF question 3
Never a few times Sometimes Most times Always
IIEF question 4 Mean SD Mean SD Mean SD Mean SD Mean SD
Never 0.74 0.18 0.79 0.17 0.82 0.17 0.82 0.15 0.84 0.17
a few times 0.77 0.18 0.83 0.16 0.85 0.16 0.86 0.15 0.88 0.16
Sometimes 0.79 0.16 0.85 0.14 0.87 0.14 0.90 0.13 0.91 0.13
Most times 0.81 0.17 0.86 0.15 0.88 0.14 0.94 0.12 0.93 0.13
Always 0.82 0.17 0.87 0.15 0.91 0.13 0.94 0.11 1.00
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On basis of the clinical trial data and the values for the health states of erectile
dysfunction, it is possible to estimate how much utility is gained as a result of Viagra
treatment. To that end, the distribution of patients over the different health states at
baseline and at end-of-treatment must be multiplied by the values of the general public
for each health state. The distribution over the different health states of erectile
dysfunction at baseline and at end-of-treatment of the patients in the Viagra group in the
trail of Goldstein, Lue, Padma-Nathan et al. (1998) is illustrated in Figure 1.
The mean utility in the sildenafil group is 0.80 at baseline and 0.91 at end-of treatment;
the mean utility in the placebo group is 0.81 at baseline and 0.82 at end-of treatment.
The mean utility gain must be controlled for the utility gain in the placebo group. This
means that the utility gain is calculated as the utility gained in the Viagra group minus
the utility gained in the placebo group: (0.91-0.80) – (0.82 – 0.81) = 0.11 (rounded
numbers).
The utility gain of Androskat could not be calculated in the same way as the utility gain of
Viagra, because the effectiveness of Androskat has not been measured with the IIEF.
We therefore had to assume that the mean utility gain of Androskat is similar to the
mean utility gain of Viagra: 0.11.
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Figure 1: The distribution of the patients in the Viagra group over the different ED-states
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3.2. Costs
The number of consults, the number of prescriptions, the prescription method and the
frequency of use are the main elements of the total costs of treatment. We therefore
analysed the resource use in these units and determined for each unit a cost price.
Resource use
In the treatment of erectile dysfunction three periods could be recognised, in which
resource use is notably different:
¨ In establishing the effective dosage
¨ In the remaining part of the first year
¨ In each following year
For each period the resource use is separately presented in terms of the number of
consultations, the number of prescriptions, the prescription method and the frequency of
use.
Establishing the effective dose
When a patient presents himself with complaints about his erectile function, the
physician executes an anamnesis. After the diagnosis is determined, a treatment must
be chosen. In some cases an additional diagnostic consult is necessary to determine the
therapy of choice. After the choice of treatment has been made the effective dosage of
Androskat or Viagra has to be established. To that end each patient pays several visits
to the physician, in which different dosages are tested and the efficacy and side-effects
are evaluated. After a new dosage is tested an evaluative consult is planned. These data
for Viagra and Androskat are summarised in Table 3.
Table 3: resources used during establishing the effective dosage
VIAGRA Scenario
Low Base High
Consultations Duration anamnesis (minutes) 7.5 10 12.5
Duration consult with partner 12.5 12.5 12.5
(% receiving separate consult with partner 0% 10%) 20%
Duration diagnostic consult 12.5 12.5 30
(% receiving diagnostic consult 10% 18%) 25%
Duration of evaluative consult 7.5 7.5 7.5
(Mean number of evaluative consults 2 2.5) 3
Number of weeks before effective dose is established 8 9 10
Medicine Number of pills 8 10 12
Prescriptions Number of prescriptions 2 2.5 3
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Table 3: resources used during establishing the effective dosage
ANDROSKAT Scenario
Low Base High
Consultations * Duration anamnesis (minutes) 10 10 10
Duration consult with partner 12.5 12.5 12.5
(% receiving separate consult with partner 0% 10%) 20%
Duration diagnostic consult 12.5 12.5 30
(% receiving diagnostic consult 25% 33%) 40%
Duration of evaluative consult (minutes) 7.5 10 12.5
(Mean number of evaluative consults 2.4 2.3) 2.2
Number of weeks before effective dose is established 14.4 9.4 4.4
Medicine Number of injections 12 11.5 11
Prescriptions Number of prescriptions 2.4 2.3 2.2
* Note that all patients need a referral from the general practitioner to the urologist. This is not the case for treatment with Viagra,
because the patients on Viagra treated by the urologists would have been treated by the general practitioner, when they would have
used a normal entry point of health care for treatment of erectile dysfunction.
The first year
Viagra is effective in about 65% of the patients. After successful establishment of the
effective dose, the patients can continue to use Viagra as often as they want and can
afford (up to a maximum of once a day). In Table 4 presents the resource use based on
a frequency of intercourse of ones a week, in order to make comparisons with Androskat
possible.
Table 4: Resources used during the first year
Viagra scenario Androskat scenario
Low Base High Low Base High
Consultations Number of routine controls 1 2 4 2 2 3
Duration of routine controls 7.5 7.5 7.5 7.5 7.5 7.5
Medicine Number of pills/ampuls** per week 1 1 1 1 1 1
Number of weeks left year 1*** 44 43 42 37.6 42.6 47.6
Prescriptions Number of pills/ampuls per prescription 14.66 5.5* 5.5* 10 10 5
Number of prescriptions 3 7.8 7.6 3.8 4.3 9.5
* This is the mean number of pills per prescription in the first three months of Viagra use in The Netherlands2 (source: Stichting
Farmaceutische Kengetallen, 1999). For most patients it is too expensive to buy more pills at once. The number of pills might increase
when Viagra would be reimbursed. The protocol provides for a prescription for 24 pills and for 3 prescriptions at a yearly basis Note
that more pills per prescription lowers the costs.
** The number of Androskat ampules is bound to a maximum because of the possibility that fibrosis develops in the penis.
*** The number of weeks are shorter in the high scenario, which is consistent with the high scenario in which the period to establish
the effective dose was longer. Note that the costs are higher when the period to establish the effective dose is longer and remaining
part of the first year is shorter than the other way around. The high and low costs scenarios therefore originate in the period to
establish the effective dose.
Each following year
The Viagra protocol provides for routine examination by the physician every three
months. It is however likely that lesser visits to the physician will take place as long as
patients are satisfied with the therapy. When necessary, there will be room to discuss
problems when a patients contacts the physician for a new prescription (Table 5)
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Table 5: Resources used during the first year
Viagra scenario Androskat scenario
Low Base High Low Base High
Consultations Number of routine controls 1 1,5 3 1 1.5 2
Duration of routine controls 7.5 7.5 7.5 7.5 7.5 7.5
Medicine Number of pills/ampules** per week 1 1 1 1 1 1
Number of weeks left year 1 52 52 52 52 52 52
Prescriptions Number of pills per prescription 12 5.5* 5.5 10 10 5
Number of prescriptions 4.3 9.5 9.5 5.2 5.2 10.4
* This is the mean number of pills per prescription in the first three months of Viagra use2. For most patients it is too expensive to buy
more pills at once. The number of pills might increase when Viagra would be reimbursed. In that case the costs would be lower.
** The number of Androskat ampules is bound to a maximum because of the possibility that fibrosis develops in the penis.
In our base scenario, we assumed the number of consults of patients treated with Viagra
to be equal to the number of consults of patients treated with Androskat. The protocol of
Viagra suggests more visits, probably because the long-term effects of Viagra are yet
unknown.3 Nevertheless, we assumed that it is not likely that patients on Viagra would
need more visits than patients on Androskat do, because the treatment is less invasive
and the side effects are only minor.
Cost per unit
The number of consults, the number of prescriptions, the prescription method and the
amount of medicine used are the main elements of the total costs of treatment. In the
previous section we estimated the volumes of these units. In the next section we
describe the cost prices for each unit (Table 6).
The costs of a consult with the general practitioner and the costs of a consult with an
urologists, represent all costs involved with a consultation, such as personal,
accommodation, and equipment. For the calculation a method is used in which the costs
of a consult with the urologists are described in two pieces: costs of the capacity (which
summarise all costs related to the hospital) and costs of the specialist, which are
calculated on basis of the estimated duration of an out-patient visit.4 Consultation costs
of a visit to the general practitioner are described in a lump sum, referring to the mean
costs of a short visit to the general practitioner.
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Table 6: Cost prices for resources used in treatment with Viagra or Androskat in NLG (without VAT)
Viagra Dose 25 mg 50 mg 100 mg
Effective dosage 25% 62% 13%
Blister pack containing 4 Viagra pills 51.89 62.88 76.32
Mean cost price per pill * 15.47
Androskat Pack containing 5 ampules Androskat (2 ml) 63.35
Mean cost price per injection 12.67
Consultations General practitioner 36.85
Urologist** 60.00 + 4,60 per minute
Prescriptions Prescription rule*** 11.20
* The mean cost price per pill is based the ‘effective dose distribution’ across the different strengths of Viagra.
** This is an estimation of the weighted mean of the costs per consultation in University hospitals and peripheral hospitals.
*** There are no costs calculated for getting a prescription, because prescriptions are given during a visit, and can be repeated without
a visit. The only prescription relate dcosts therefore are the costs of the ‘prescription rule’: this is a lump sum charge to refund
pharmacy costs. This charge is independent of the prescribed medicine or the amount prescribed.
Patient flows
In this part of the cost analysis we compare the treatments Viagra and Androskat. In
estimating the costs of both treatments, we created two scenarios: a) the Viagra
scenario in which both Viagra and Androskat will be reimbursed, and b) the androskat
scenario, in which only Androskat is reimbursed. This means that in the Viagra scenario
it is possible to try Androskat when Viagra fails, but in the Androskat scenario the use of
Viagra is not possible after Androskat fails (see figure 2).
In the first period after the release of Viagra, from October to December 1998 about
129,000 Viagra tablets have been sold.2 The tablets were sold to men who had not
received any prior treatment before, but also to patients who had received other
treatments before, such as Androskat. This means that irrespective of reimbursement,
Viagra has already become the preferred treatment for many patients. The patient flows
in the Viagra scenario are therefore most likely the current patient flows and the
Androskat scenario describes the patient flows before the release of Viagra.
Note that figure 2 only presents the patient flows in the first year. However, it is important
to realise that after the first year 10% of the Viagra patients have ended treatment,
whereas this number is 14% for the Androskat patients. The percentage of patients
ending treatment will be the same for patients on Andsroskat and Viagra from the
second year on: 5%. Our calculations are concerned with costs per patient, costs per
QALY and costs per additional QALY. A similar dropout rate will not influence these
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parameters. This means that these parameters are constant from the second year on.
We therefore present the outcomes for the first year and for each following year.
Figure 2: Patients flows for the two different scenarios: The Viagra scenario or the Androskat scenario*
 * This refers to personal communiaction with the clinicians cooperating in our study: EJH Meuleman, MD. Ph.D. of the University Hospital
St. Radboud in Nijmegen, urology department and M Caffa, M.D. of the hospital St. Antoniushove in Leidschendam. Their estimates are based
on their experiences with Viagra in the clinical trial but also in daily practice.
In the clinical trials with Viagra efficacy is assessed with a global efficacy question (“Did
the treatment improve your erections?”), with a response of yes or no. The end points of
the IIEF quantified the magnitude of the response.1 In daily practice patients with a
limited improvement in the erection might not continue the use of Viagra and also
patients with side-effects might not continue the use of Viagra. This means that the
effectiveness is lower than the efficacy. Therefore, we did not use the outcomes of the
global efficacy question (which indicated efficacy of 78%) in the model of our patient
flows, but we used the percentage of patients who continued treatment after establishing
Viagra scenario
Continuation of use (65%)
Effective (65%)
Source: Reference 5
(Meuleman et al. 1998)
and personal communication*
No other treatment (10.5%)
Effective (12.25%)
Source: personal communiaction*
No response (12.25%)
Androskat treatment (24.5%)
Source: Reference 6
(Lycklama à Nijeholt, 1998)
No response (35%)
Viagra traject (100%)
ED patient reports
(100%)
Effective (64%)
Source: Reference 7 & 8:
(Korenman, 1998;
Jackson and Lue, 1998)
No response (36%)
Androskat traject(70%)
Source: Reference 6
(Lycklama à Nijeholt, 1998)
No treatment (30%)
ED patient reports
(100%)
Androskat scenario
33
the effective dose (based on estimates from the clinicians participating in this study:
Viagra is estimated to be effective in 65% of the patients).
Cost calculations
The calculation of treatment costs is based on the presented volumes of resource use,
the costs per unit of the resources and the patient flows. In the determination of the
treatment costs we first of all determined for each stage of treatment the volumes of
resource used and the cost prices (see Table 4). For the calculation of total costs on
basis of these figures it should be noted that 80% of the patients on Viagra are treated
by the general practitioner, whereas this percentage is only 10% for Androskat users.
The costs for referral to the specialist are included in the calculations. The treatment
costs are summarised in Table 7.
Table 7: Costs in different treatment periods following the patient flows (in NLG)
Scenario Effective Physician Costs establishing
effective dose
Costs remaining part
first year
Costs for each
following year
Viagra Viagra is effective General practitioner 321.81 786.67 908.24
(Viagra) Urologists 565.31 901.97 977.47
Weighted mean 370.51 809.73 922.09
Viagra is not effective General practitioner 308.73 555.47 772.36
(Androskat) Urologists 621.85 699.59 841.58
Weighted mean 590.54 685.18 834.66
Androskat Androskat is effective General practitioner 308.73 679.58 772.36
Urologists 621.85 823.70 841.58
Weighted mean 590.54 809.29 834.66
When these figures are combined with the patient flows presented in figure 2, the
treatment costs of erectile dysfunction can be calculated in the two different situations:
the Viagra scenario and the Androskat scenario. In these calculations the costs of
patients in which treatment yielded no response are added to the costs of patients in
which therapy was successful.
Some patients discontinue treatment during the first year, namely 10% for Viagra and
14% for Androskat. This dropout is not caused by a medical factor, and it is unknown
when this dropout takes place. We modelled the costs assuming that each patient would
continue to use treatment for a whole year, because it is unknown when this dropout
takes place. Note that this modelling overestimates the costs.
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The first year
In the Viagra scenario 77.25% of the patients will be treated successfully: 65% with
Viagra, and an additional 12.25% with Androskat. The mean costs of the 65% of patients
in which Viagra is successful amounts NLG 1180.24. In the 12.25% patients in whom
Androskat is successful, the mean costs amount NLG 2912.97 in the first year. This last
figure is build up of the costs of establishing the effective dose of Viagra in the 35% in
which Viagra failed, and the subsequent establishing of the effective dose of Androskat
in 24,5% and continued use of Androskat in 12.25% for the first year. The mean costs
per successfully treated patient in the Viagra scenario in the first year are estimated at
NLG 1455,01 (weighted for use of Androskat and Viagra).
In the Androskat scenario, the mean costs per successfully treated patient are estimated
at NLG 1732.01 in the first year. This means that Androskat is more costly in the first
year, although the medicine is less costly. This can be explained by the high number of
consultations with the specialist involved in establishing the effective dose; the costs of
the general practitioner (80% in the Viagra scenario) are lower. Also the costs of non-
successfully treated patients are therefore relatively high in the Androskat scenario.
Together this explains the higher costs in the Androskat scenario in the first year.
Androskat treatment would only be effective in 44.80% in the first year as compared to
77.25% in the Viagra scenario.
Each following year
The next year starts with 10% less Viagra users and 14% less Androskat users. The
number of patients using Viagra and Androskat decreases 5% per year from the second
year on. For the Androskat the costs are NLG 834.66 for the second year, for Viagra the
costs are NLG 922.09. This means that the mean costs in the Viagra scenario are NLG
908.75 (weighted for use of Androskat (10.5% in the second year) and Viagra (58.5% in
the second year)). Note that all costs of non-successfully treated patients were
accounted for in the first year figures of successfully treated patients. This means that
from the second year on, the costs per successfully treated patient are constant (when
the frequency of use remains constant). Therefore, the costs in each following year will
be the same as the costs per successfully treated patient in the second year.
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Summary
In sum, the treatment costs in the Viagra scenario and the Androskat scenario were build
up of the number of consults, the number of prescriptions, the prescription method and
the amount of medicine used. The main cost-driver is the medicine itself, both for
Androskat and Viagra. The cost price of Viagra is higher than the cost price of
Androskat. However, in the Androskat scenario the consultation costs are higher. The
number of prescriptions hardly influences the difference in costs. In the first year the
Androskat scenario is more costly, but in the following years the costs per successfully
treated patient are higher in the Viagra scenario (summarised in Table 8)
Table 8: Summary of costs of Viagra and Androskat (NLG)
Viagra scenario Androskat scenario
First year 1455.01 1732.01
Each following year 908.75 834.66
3.3. Cost-effectiveness
The utility gain of successful treatment for erectile dysfunction is estimated at 0.11
QALY. In the Viagra scenario the costs are estimated to be NLG 1455.01 in the first year
and NLG 908.75 in each following year. The costs per QALY in the first year are:
1455.01/0.11 = NLG 13227.36 per QALY. In each following year the costs are 8261.36
per QALY. In the Androskat scenario the costs are estimated at NLG 1732.01 in the first
year and on NLG 834.66 in each following year. The utility gain is assumed to be
comparable, thus 0,11. This means that the costs per QALY in the first year are NLG
15745.55 and in each following year NLG 7587.82.
To analyse the additional costs and effects of Viagra scenario when compared to the
Androskat scenario, we performed an incremental analysis. This means that the
additional costs and additional effects of the Viagra scenario are compared. On basis of
the prior reported results, this can be calculated with formula 1.
Formula 1:  
11.080.4411.025.77
01.173280.4401.145525.77
´-´
´-´
Formula 2:  
11.053.3811.053.69
66.83453.3875.90853.69
´-´
´-´
36
This would results in NLG 9750.80 per additional QALY in the Viagra scenario as
compared with the Androskat scenario in the first year. For the second year the
increment would be NLG 9098.52, as represented in formula 2.
So far we have used the artificial distinction between the first year and each following
year. Below we explored what happens to the cumulative costs and effects when this
distinction is not made. To that end we calculated the cumulative costs and effects of the
Viagra and Androskat scenario for periods of multiple years. This means for example
that the figures after 2 years are build up of the costs and effects of the 77.25
successfully treated patients in the first year and the costs and effects of the 69.53
successfully treated patients in the second year.
Table 9: Cumulative costs and effects of Viagra and Androskat at long-term (costs in NLG per QALY)
Viagra scenario Androskat scenario
% patients
continuing treatment
Costs per
QALY
% patients
continuing treatment
Costs per
QALY
Incremental costs
per QALY
After 1 year 77.25 13227.36 44.80 15745.55 9750.80
After 2 years 69.53 10875.05 38.53 11973.41 9432.44
After 3 years 66.05 10063.90 36.60 10643.93 9326.63
After 4 years 62.75 9653.47 34.77 9950.24 9273.65
After 5 years 59.61 9405.90 33.03 9543.57 9242.07
After 6 years 56.63 9240.48 31.38 9255.76 9221.08
After 7 years 53.80 9122.27 29.81 9056.01 9206.12
As presented in table 9, the Viagra scenario is approximately effective in 20 to 30% more
patients than the Androskat scenario is. Furthermore, the costs per QALY of the Viagra
scenario are lower until the 7th year of treatment as compared to the Androskat scenario,
despite the higher medication costs. The cost driver in the Androskat scenario is that
Androskat is prescribed by the urologist, which means that also the costs of non-
successfully treated patients are relatively high. These costs are added to the costs of
successfully treated patients. Our figures show that the higher costs of the Androskat
scenario in the first year have a strong impact on the cost-effectiveness of this treatment.
3.4. Sensitivity analysis
We perform sensitivity analysis with respect to three subjects:
1. The frequency of intercourse
2. Different values for erectile dysfunction
3. The uncertainty with respect to the volumes of resource use.
These 3 subjects will be discussed separately.
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Frequency of intercourse
As indicated before, the use of Androskat is limited for medical reasons to once a week.
This is not the case in Viagra, which can be used daily (but only one dose per day).
Therefore we analysed how much the frequency of use affects the costs and the costs
per QALY and how this affects the increment between the costs and effects of Androskat
and Viagra. This is summarised in Table 10. One can see that the results are highly
influenced by the frequency of use.
Table 10: Sensitivity of cost-effectiveness ratios in the Viagra scenario for frequency of intercourse (in NLG)
First year Each following year
Frequency of
use per week
Mean
costs
Costs per
QALY
Costs per additional
QALY  (%)
Mean
costs
Costs per
QALY
Costs per additional
QALY (%)
1 1455.01 13227.36 9750.80 (100.00) 908.75 8261.36 9098.52 (100.00)
1.5 1754.96 15954.18 16242.22 (166.57) 1270.15 11546.82 17012.56 (185.10)
2 2054.92 18681.09 22733.86 (233.15) 1631.55 14832.27 24833.86 (270.19)
Different values
The differences that occur because of the differences between values of the patients
and values of the general public are presented in Table 11. Note that the higher values
of the patients result in a better cost-effectiveness ratio.
Table 11: Sensitivity of cost-effectiveness ratios in the Androskat and in the Viagra scenario for different values (in NLG)
Source of Values First year Each following yearQALY
gain Costs per
QALY
Viagra
Costs per
QALY
Androskat
Costs per
additional QALY
(100%)
Costs per
QALY
Viagra
Costs per
QALY
Androskat
Costs per
additional
QALY (100%)
General public (group) 0.11 13227.36 15745.55 9750.80 (100.00) 8261.36 7587.82 9098.52 (100.00)
Students (group)* 0.11 13227.36 15745.55 9750.80 (100.00) 8261.36 7587.82 9098.52 (100.00)
Students (individual)* 0.12 12125.08 14433.42 8938.23 (91.66) 7572.92 6955.50 8425.31 (91.66)
Patients (individual) 0.14 10392.93 12371.50 7661.34 (79.57) 6491.07 5961.86 7221.70 (79.57)
* Source: This report, appendix A9. Note that these data suggest that the QALY gain as assessed by the general public might have
been higher when TTO would have been done individually instead of in groups.
These figures not only present a sensitivity analysis for the source of our values, but also
for our method of time trade-off. As described in appendix A, the TTO in groups resulted
in somewhat higher values for mild states of erectile dysfunction. When these values are
combined with the frequency distribution over different health states, this resulted in a
different utility gain: 0.11 in group sessions and 0.12 in individual TTO. Note that in
groups the values for students and the general public are the same. Therefore it could
be expected that individual TTO in the general public could yield the same result as
individual TTO in students: 0.12.
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Uncertainty regarding resource use
The differences that occur because of different scenarios about resource use are
presented in Table 12.
Table 12: Sensitivity of cost-effectiveness ratios in the Viagra scenario for uncretainty regarding resource use (in NLG)
First year Each following year
Scenario Mean
costs
Costs per
QALY
Costs per additional
QALY (%)
Mean
costs
Costs per
QALY
Costs per additional
QALY
Low 1320.65 12005.91 6843.02 (71.18) 860.84 7825.82 8154.40 (89.72)
Base 1455.01 13227.36 9750.80 (100.00) 908.75 8261.36 9098.52 (100.00)
High 1568.56 14259.64 12208.21 (125.20) 1015.92 9235.64 11510.59 (125.23)
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4. Discussion
4.1. Summary
In this investigation we demonstrated that the costs per QALY of Androskat are higher
than the costs of Viagra in the first year (NLG 15745.55 versus NLG 112399.52). The
costs of the Androskat scenario per successfully treated patient after establishing the
effective dose are lower than the costs of the Viagra scenario (NLG 7587.82 versus NLG
8261.36). However, the high costs of establishing the effective dose in the Androskat
scenario strongly influence the cost-effectiveness: the Androskat scenario yields higher
costs per QALY until the 7th year. In the following years, Viagra is more costly, but is also
more effective in the sense that more patients can be treated. For example after 7 years,
53.80% of the patients in the Viagra scenario is continuing treatment, whereas this is
only 29.81% in the Androskat scenario. Note that these figures are relevant in an
incremental analysis of the additional effects of Viagra as compared to Androskat. This
incremental analysis shows that the higher costs of the Viagra scenario are in line with
the higher effects; for example, the additional costs per additional QALY are estimated to
be NLG 9206.12 in the 7th year.
It must be noted that these comparisons can only be made on the assumption that the
effects and the frequency of use are the same for Viagra and Androskat, as is the impact
on quality of life. The results of the sensitivity analyses show that the cost-effectiveness
ratios are robust for differences between patients’ values and values of the general
public and for the uncertainties regarding the other assumptions in our model. All
presented cost effectiveness ratios are favourable: as well the ratios for Androskat and
Viagra therapy as the ratio of the increment between costs and effects in the Viagra and
Androskat scenario.
In valuing disease specific outcomes we introduced two methodological novelties. The
first is that we collected values for health states described in disease specific instead of
generic terms. The second novelty is that we collected TTO values in groups. Therefore
we analysed in appendix A the possibility to value the health states defined by the IIEF
with TTO in groups. The validity of the methods we used, proved to be good (see
appendix A).
40
The results of appendix B showed that both patients and the general public consider
erectile dysfunction to have a substantial impact on quality of life. The values given to
health states of erectile dysfunction by patients were lower than those of the general
public were. Hence, when the patients value the effects, the cost-effectiveness of Viagra
improves. This effect is shown in the sensitivity analysis, where the model is tested for
the differences between values of patients and the general public.
Within the general public, values were not related to age, gender, the availability of a
partner, sexual activity and sexual satisfaction. Only one background variable seems to
have a relation with the values given: subjects without children gave lower values for
health states of erectile dysfunction. This means that the cost-effectiveness of Viagra
improves when used in subjects without children.
4.2. Limitations
In our comparison of the costs and effects, we had to deal with the fact that the use of
Androskat is rationed for medical reasons: too many injections can cause fibrosis in the
penis. To enhance the comparability of the use of Androskat and Viagra, we compared
both alternatives by assuming the same frequencies of intercourse. However, the use of
Viagra is less rationed for medical reasons. In the sensitivity analysis we analysed how
changes in frequency of intercourse with Viagra influence the cost: the costs of treatment
increase almost linearly if the frequency of use of Viagra increased. This also means that
the cost-effectiveness is almost linearly related to the frequency of use. Because the use
of Androskat is limited, this means that the costs per additional QALY rise exponentially
when the frequency of use increases.
In this context it should be noted that treatment of erectile dysfunction is valued as a
relative increase in successful attempts of intercourse, without restriction of the number
of attempts of intercourse as is the case with Androskat. Furthermore, the TTO protocol
for valuation of the health states of erectile dysfunction, provides for cure with oral
treatment. It can be assumed that a protocol that provides for cure with an invasive
treatment, such as injections with Androskat, would yield lower values. For instance the
lower continuation rates for Androskat therapy after the first year might indicate that the
quality of life effect of Androskat is lower. Thus, to use the same utility gain in Androskat
and Viagra is a conservative approach in the incremental analysis of costs and effects of
Viagra as compared with costs and effects of Androskat.
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The trial design of Goldstein, Lue, Padma-Nathan et al. on which we based our estimate
of the clinical effect, was analysed on an “intention to treat” basis.1 That means that also
patients who do not respond to Viagra remain in the trial. There is no doubt that an
“intention to treat” design can demonstrate the efficacy very convincingly. However, such
design may not be the most appropriate design for the estimation of the effect of Viagra
in patients who continue to use the medication. In the estimation of the  utilities gained,
we summarised the effect in patients in which Viagra yielded sufficient response and in
patients in which Viagra yielded no response (in 35% of the patients). This means that
we underestimated the utility gain of patients who will continue treatment. The estimation
of the effect of Viagra is also in that respect conservative.
We used the values of the general public. It is remarkable that the values of the general
public were higher than values of patients, which means that the general public judges
the impact on quality of life to be milder than patients do. In most research this is the
other way around.2 This means that in this case the “clinical selection bias” and the
“strategic bias” are more dominant than the adaptation process. As explained in
appendix B, this could be expected in a situation in which patients participate in a trial
with an effective intervention. On the other hand, it could also mean that the awareness
of the problems of erectile dysfunction in the general public is low. However, for our
purposes it is not necessary to further investigate this difference, because the values of
the general public will give a conservative estimate of health care interventions.
There were no relevant systematic differences in absolute values between the individual
and the group administration of the TTO. There were however some small differences at
the level of the individual health states: the better erectile dysfunction states were valued
lower in TTO in groups than in individual TTO. Though this only applies to 4 states of
erectile dysfunction, there is an effect on the utility gain in the patient population; the
utility gain is 8.3% higher when assessed with individual TTO as compared with TTO in
groups. The same difference between TTO in groups and individual TTO could also be
expected in the general public. That means that the costs per QALY and the costs per
additional QALY could be expected to be 8.3% lower when assessed with individual
TTO. Given that we used group sessions for the evaluation of erectile dysfunction, we
made again a conservative estimation of the cost-effcetiveness.
One can argue that we only established a validity test of the group sessions in students,
and therefore we are still uncertain about the validity of group sessions in the general
public. However, we do think that the results of the student investigation can be validly
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generalised to the general public for two reasons. First of all, the group sessions in the
general public were not more difficult to administer than in students. A second reason is
that the differences between our group protocol hardly differed from an individual
administration. Comprehension of the valuation task is tested on an individual level, and
as soon as the investigator notes signs of misinterpretation of the task, an intervention at
an individual level takes place.
We did not present the influence of the background variables in patients. Given the
homogeneous composition of this group in terms of the background variables, we did not
expect that the statistical power of the investigation would be strong enough to detect
any influence. We indeed could not detect any significant relation in the patient
population.
The sample of the general public was not completely representative in terms of the
distribution of age categories. However we did not want to stratify the results for this
observation, because age did not have significant influences on the values of the health
states.
4.3. Implication for theory
A specific implication of our research is that we now are able to recalculate the outcomes
of the Viagra trial of Goldstein, Lue & Padma-Nathan et al. (1998) into QALYs. A more
general implication is that this means that we have proceeded in the application of
QALY-theory: we have demonstrated that it is possible to attribute utilities to health
states as defined by a disease specific questionnaire and that this can be done in a cost-
effective way. This enlarges the area of application of QALY-analysis. It seems even
possible to recalculate disease specific outcomes of trials to QALYs. Furthermore, the
enhanced validity of the group sessions open up the possibility for researchers to quickly
assess the utility of different scenarios, which will facilitate model studies in health
sciences.
It seems that the relations between the values for health states of erectile dysfunction
and background variables are restricted to having children and being a patient with
erectile dysfunction or not. The robustness of values of hypothetical health states for the
influences of social economic variables has been reported several times. Handbooks
and literature studies report that the influences of these variables seem limited.2, 3 The
lack of influence of background variables on the values of the general public indicates
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that in that respect there is no need for different cost-effectiveness ratio for different
subgroups. An exception might be for the couples who have trouble getting children
because of the erectile dysfunction. In these couples the cost-effectiveness of Viagra is
better: the costs per QALY gained are lower.
We did not determine different cost-effectiveness ratios for different patients groups on
the basis of differences in efficacy. We could not do this, because such differential
efficacy data is lacking. If such differential data becomes available in terms of outcomes
of the IIEF, adaptation of our estimates of the cost-effectiveness are easily made. Given
that the placebo effect can be expected to be negligible (Goldstein, Lue, Padma-Nathan
et al.,1998), it must not be very difficult to obtain this information.
4.4. Policy implication
We estimated the cost-effectiveness of Viagra and compared this in a conservative way
with the cost-effectiveness of Androskat, which is already reimbursed in The
Netherlands. Compared in that way, the cost-effectiveness of both products is about the
same. Furthermore, the cost-effectiveness ratio of Viagra lies at the favourable end of
the scale when compared with interventions in health care for other diseases.4 Given the
outcomes of these comparisons, reimbursement of Viagra should be considered.
If reimbursement of Viagra is considered, the rationing of the medication should be a
focus point of the distribution, because the frequency of use is the major cost driver of
Viagra. That means that the allocation of resources to Viagra can be controlled by
rationing or by a partial reimbursement of the medication.
If the reimbursement of Viagra is considered, monitoring the effects in terms of the IIEF
and frequency of use per subgroup can be considered. Both variables are the major
determinants of the cost-effectiveness, and therefore essential parameters in
determination of an allocation strategy per subgroup based on cost-effectiveness
arguments.
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Abstract
Introduction
Health economists have a preference to measure quality of life in terms of utilities,
because this offers the possibility to integrate this outcome with life expectancy into
QALYs. These utilities are often collected with the use of standardised questionnaires
like the EuroQol or the HUI. These questionnaires are said to have a low sensitivity, as
compared to specific questionnaires. An alternative would be to value the outcome of
disease specific questionnaires in terms of utilities. To our knowledge, we are the first to
apply and describe this strategy. For the valuation of disease specific outcome we used
time trade-off (TTO) in both standard individual interviews and group sessions, in order
test the possibilities of a more cost-effective administration.
Methods
169 subjects form the general public and 117 students valued 28 health states as
defined by the International Index of Erectile Function (IIEF) with TTO. All members of
the general public and half of the students valued the states in a group session. The
other half of the students valued the states in individual sessions.
Results
There were small differences between the values of the group administration and the
individual administration, but there was no overall effect. The factor structure was also
similar. The values showed good content validity.
Conclusions
The results support the validity of the proposed process of valuing the outcomes of
disease specific questionnaires into utilities. The administration of TTO can be done in
group sessions, which reduces the costs of the administration.
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Introduction
Quality of life can be measured with disease specific questionnaires, generic
questionnaires and in terms of utilities. Health economist have a clear preference for
utilities, because these outcomes can be integrated with life expectancy into “Quality
Adjusted Life Years” (QALYs). Normally, health economists collect the values or utilities
for health states with the use of standardised questionnaires like the EuroQol or the
Health Utility Index. Typically, these instruments are generic questionnaires: they can be
used in all kinds of patient populations. This generic entity enlarges the area of
application, but at the same time lowers the sensitivity of the instrument, because the
questionnaire may not contain items directly related to specific aspects of the illness.
Brazier and Dixon (1995) therefore suggest to adapted disease specific quality of life
questionnaires for the measurement of the utilities. So far, such efforts have been scarce
and the methodology has not been thoroughly described. In this manuscript we describe
such valuation process in which the general public attributes utilities to the health states
defined by the International Index of Erectile Function (IIEF).
Doubts about the sensitivity of generic quality of life questionnaires in general and of
utility measurement in particular are widespread.1 For instance, Kantz, Harris & Levitsky
et al.2 Spectus, Winder, Dewhurst et al.3 and Gliklich & Hilinski4 all concluded that their
disease-specific instrument was more sensitive than the SF-36 survey. A similar opinion
exists for utility measurements.5, 6 Brazier & Dixon7 begin their article with the
statement: “…There is increasing concern over the use of health utility measures in
economic appraisal for valuing health. These measures have been criticised for not
capturing all relevant aspects of a condition (Hall, Gerard & Salkeld, 1992), being
insensitive to lower levels of perceived ill-health (Brazier, Jones & Kind, 1993), and for
the general failure on the part of economists to test the relevance of their measure for
the intervention and condition being evaluated (Carr-Hill & Morris, 1991)…”.
Because of these drawbacks, health economists have tried to adapt their generic
measures to the specific circumstances of the illness. In the past, several ad hoc
methods were used, like for instance using “experts” to attribute values to patients in the
trial.8 Others followed the instructions of Gold, Patrick & Torrance et al.9 and mapped
the outcomes of disease specific measure “afterwards from behind the desk” into utility
instruments like the EuroQol and the Rosser Index.10, 11, 12
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A more structural solution is to generate a small number of holistic scenarios, which are
disease specific and adequately describe the main differences between patient
subgroups. The scenarios are then valued in a separate investigation.13, 14 By
classifying the patients in these scenarios, the researcher can attribute utilities to the
patients in the trial. A major disadvantage of such approach is that only a small number
of scenarios can be generated. Therefore these scenarios mean a significant reduction
of clinical information. This reduces the sensitivity for small changes in health. So in this
approach the health states descriptions may be specific, but they are also rigid and
limited in number.
To overcome these problems there have been attempts to make disease specific
classification systems suitable for the calculation of utilities or to make generic
instruments more sensitive to disease specific problems. For instance Mohide, Torrance
& Streiner et al.15 attempt to make a disease specific classification system for the health
states of caregivers. Krabbe, Stouthard & Essink-Bot et al.16 tried to adapt the EuroQol
EQ-5D, a questionnaire already suitable for the calculation of utilities. They tested the
effect of adding a cognitive dimension to the 5 dimensions of the EuroQol EQ-5D. In
both cases, the authors conclude that their new system adequately classified their
patient group. However, the problem remained that utilities could only be attributed to
some of the health states, because the recourses did not allow for a complete valuation
of the classification system.
Of course one could overcome all these problems by asking the patients in the trial to
value their own health with the use of utility measures like standard gamble and time
trade off. However, there are several drawbacks for this design.
First of all the approach is extremely labour intensive, as the measurement has to be
done within an interview session by specially trained personnel. Especially when one
would like to measure several times during the trial, costs can be mounting.
Furthermore, many quality of life researchers have been experiencing reservations in
clinicians to use interview techniques like standard gamble and time trade-off in patients,
like we did.7, 17 Although justification of such reservations is not given in the literature,
resistance can be insuperable. In that case the only remaining direct utility measurement
by patients is a visual analogue scale. However, the performance of a visual analogue
scale as a utility instrument in the economic evaluation of health care is low.9
A third argument against the use of direct utility measures by patients is the issue of the
perspective of the measurement. In the economic appraisal of health care the preferred
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perspective is the societal.18 If one chooses to value the health states by patients, one is
changing the perspective of this part of the analysis from a societal perspective to a
patient perspective. The patient perspective is not necessarily wrong in other evaluations
(for instance, it makes good sense in a clinical perspective), but as soon as the costs are
calculated form a societal perspective, it has been recognised that it makes most sense
to value the effects from the same perspective.9, 19 In appendix B, we elaborate on the
choice of the perspective in economic appraisal of health care.20
To come to a conclusion: the sensitivity of generic instruments - capable of attributing
utilities to health states - has been questioned. A good solution would be to validate
disease specific instrument in such a way that they would also be capable to attribute
utilities to health states. In the present manuscript we tested the validity of such valuation
process. In this investigation the general public attributed utilities to the health states
defined by the International Index of Erectile Function (IIEF).
The strategy above has been followed before15, 16, but it has not been fully explored,
given the costs constrains. Therefore it would be helpful if this process is further
investigated, and directed towards more inexpensive research designs. For this reason
we added an additional research question, aimed at reducing the costs of such effort:
can one collect the data validly in a group session, as compared to the usual face-to-
face interview. This additional research question was investigated in a student
population.
Methods
International Index of Erectile Function (IIEF).
To generate utilities for erectile dysfunction, we converted disease specific outcomes
into utilities. The valuation method was time trade-off (TTO).
The health states valued were based on question 3, 4 and 7 of the International Index of
Erectile Function (IIEF). This is a 15-item questionnaire to assess sexual functioning.21
Prior to the development of the IIEF, the National Institutes of Health pointed out the
need for a symptom scoring sheet necessary to aid in standardisation of patient
assessment and treatment outcome. Furthermore they pointed out the need to develop a
staging system to permit quantitative and qualitative classification of erectile dysfunction.
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The IIEF was developed in response to these needs. The IIEF is currently the preferred
disease specific questionnaire for several reasons: it is valid and psychometrically
sound, it can be used across different cultures and it contains the two primary end points
of erectile dysfunction treatment as defined by the National Institutes of Health: the
ability to penetrate and to maintain an erection.22
The IIEF has been used in the clinical trials in which the efficacy of Viagra was
demonstrated.23 If we are able to value the IIEF in terms of utilities, we are also able to
translate the outcome of the trial into utilities. The primary end points in this clinical trial
were question 3 and 4; thus the same questions as used in this investigation.
By addressing the ability to attain and maintain an erection, the IIEF has the sensitivity
and specificity to detect treatment-related changes in patients with erectile dysfunction.21
Because these two primary end points have each five response levels, they define (5 x
5) 25 unique health states (table 1). Question 7 is about the satisfaction of the
intercourse in general, without making a direct reference to erectile functioning (table 1).
The 4 health states as defined by question 7 were valued independently. The subject
valued the total of 28 health states using “time trade-off”. The best health state (no
erectile dysfunction) was not valued, because normal health is a reference point in TTO.
Table 1: Question 3, 4 and 7 of the IIEF
IIEF Question 3 IIEF Question 4 IIEF Question 7 Response level
During the past 4 weeks,
how often were you able to
penetrate?
During the past 4 weeks,
how often were you able to
maintain the erection?
When you attempted sexual
intercourse, how often was it
satisfactory for you
Almost never or never Almost never or never Almost never or never 1
A few times A few times A few times 2
Sometimes Sometimes Sometimes / Most times 3
Most times Most times Almost always or always 4
Almost always or always Almost always or always 5
Valuation method (TTO)
Time trade-off (TTO) is, next to standard gamble, one of the preferred valuation methods
in health economics that are used to determine the values or “utilities” of health states.
The methodology of this interview technique is described in detail in Drummond, O'Brien
& Stoddart et al. (1997). Based on this standard work, one has to make some
methodological choices to be able to operationalise the method for the specific research
question. These methodological choices are motivated below.
As usual in this kind of valuation tasks, the subjects had to value the health states “for a
person like themselves”. Thus the subjects had to imagine that they had an erectile
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dysfunction as described by the 25 health states. This means for example that older
subjects gave values from an ageing perspective, while persons without a sexual active
partner could incorporate this circumstance in their values. The only exception was
gender: women had to imagine that they were men with erectile dysfunction.
The health states of erectile dysfunction were assumed to be chronically. This means
that the subjects had to assume that they were in the health states for the rest of their
lives, other things being equal to their own present and further situation.
The trade-off in time was measured relative to the life expectancy of the subjects. The
subjects had to assume that they would reach their life expectancy in “normal health for
that age”.
The health states were presented on cards in random order. Subjects were allowed to
reshuffle the cards. They were also allowed to go back to a former response, if they had
changed their mind during the interview. Because of the large number of states that had
to be valued and because of the intimacy of the subject, it was chosen to let the
respondents record the answers on an answer form instead of letting the interviewer
record the responses. The cards had numbers that corresponded to the answer form.
The answer forms consisted of lines representing the life span of the respondent. The
respondents indicated on this line the so called “indifference point”. This point indicates
that a loss of years to gain full health for which the respondents have no preference for
living shorter as indicated on the line in full health or living their complete life span in the
health state described on the card. This adaptation of the TTO administration was based
on the work of Bleichrodt & Johannesson.24, 25
Interview protocol
The interview protocols for individual interviews and for the TTO administration in groups
were designed to be as similar as possible.
Both protocols began with a general introduction after which the subjects practise with
TTO using the health state “sitting in a wheelchair” as an example. In the group sessions
this health states was valued by a volunteer from the group, and had the form of an
individual administration of TTO, using the typical “ping-pong interview technique”. After
this example, the group was invited to discuss the results and was encouraged to ask
questions about the procedure if they did not fully comprehend the administration. In
both the individual and the group protocol, we tested the ability to perform the task by
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valuing 3 generic EuroQol EQ-5D health states (states 11211, 11122 and 21232) with
TTO.26 In both protocols the answers were checked and discussed. If there were signs
of misinterpretation, the protocol was explained again. In the groups sessions this check
and the additional explanation was done on an individual basis.
After this check, the subjects were introduced into the health problems associated with
erectile dysfunction. Female subjects were asked to imagine themselves to be men
when valuing the problems associated with erectile dysfunction. After the introduction,
the subjects were asked to value the health states of erectile dysfunction with the use of
TTO. It was explained that some health states may appear illogical, namely states that
describe that penetration is (almost) never possible, but that patients are able
(sometimes, most times or always) to maintain the erection. Although these health states
may seem odd, inquiry about the data set published by Goldstein et al. showed that all
25 states were represented but one: “almost never being able to penetrated, but always
able to maintain the erection after penetration”.27  Because it is technically possible for
patients with erectile dysfunction to classify themselves in all states, subjects were
encouraged to value this state as well.
Twenty eight health states of erectile dysfunction as defined by question 3, 4 and 7 of
the IIEF, were printed on cards and presented randomly. During both the individual and
the group sessions the interviewer checked the responses, and if there were signs of
misinterpretation, the subjects was interviewed on an individual basis, until the subject
could perform the task independently. For this reason, if there were more than 6 subjects
in the group session, the interviewer in the group session was assisted with one or two
fellow researchers.
Invalid responses
Invalid responses were excluded from the analysis. Invalid responses were defined
according to three criteria: A) when a respondent trades more years than possible in his
life expectancy; B) when there are too many missing values (>4); and C) when subjects
did not make any trade-off during the administration of the three EuroQol health states.
Criteria A and B control for task comprehension. Criteria C refers also to “lexicographic
responders”. A lexicographic responder is defined as a subject who is not prepared to
make any trade-off for any health state, not even for a very bad health state like for
instance the EuroQol health state 21232. Lexicographic means that when a respondent
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is faced with an option, he or she will always choose for one particular alternative, no
matter how favourable the other might be. Of course, no trade-off on EuroQol state
21232 could also mean that the subject still did not understand the task. In both cases
(did not understand or a lexicographic response) the responses on time trade-off
questions becomes meaningless. When the interviewer observed such response, both
options were checked. If the respondent still did not understand the task, the task was
explained again. If the responder seemed to act in a lexicographic way, an even more
extreme health state than 21232 was proposed. If the subject maintained in his or her
lexicographic response mode, or when it was not feasible to explain the task, the
responses of the subject were excluded.
Note that the exclusion of lexicographic responders was only based on the responses on
the EuroQol health states and not on the responses on the 28 health states of erectile
dysfunction. If a respondent did not made any trade-off in case of the health associated
with erectile dysfunction, the responses were judged to be valid, as long as the subject
made a trade-off on the EuroQol states, and as long as it was clear that the respondent
understood the task.
Subjects
We tested our valuation methods in three subject groups, namely a pilot group, students
and the general public. First we piloted both the individual and the group protocol in a
group of 25 colleagues and students. The results of this “corridor investigation” were
encouraging and the protocol was refined on the basis of these experiences.
Prior to the data collection in the general public, we performed TTO interviews in a
sample of students. To test the validity of the TTO administration in groups, we divided
the student population in two parts: half of them were individually interviewed and half of
them were interviewed in a group session. Subjects were recruited using posters at the
university. The poster mentioned an interview task about health state valuation. It was
not mentioned that the health states being investigated were associated with erectile
dysfunction. We paid the students NLG 25,- (similar to 11,- Euro). An effort was made to
match the student in the individual sessions and the group sessions in respect to gender
and age.
Blauw Call Centre, a marketing research bureau, recruited a representative sample of
the general public from a random sample of the telephone directory. The sample was
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based on quota sampling, and stratified on the basis of sex, age and education. In this
process, we allowed oversampling of the men aged 40-70 years, because this group is
the target group of Viagra. If applicable, the results could be weighted for differences in
gender and age between our sample and the national statistics. This stratification would
be done if the differences from national data were substantial and if a relationship was
found with the dependent variable of this investigation, namely the value attached to
health states of erectile dysfunction. The subjects were interviewed at the university. The
subjects were paid NLG 30,- (similar to 14,- Euro) and got a refund of their travelling
expenses. Also the sample of the general public was not notified in advance that the
health problem being examined was erectile dysfunction. Instead the study objective
was described as the valuation of some health states.
Analysis
The analysis aimed to answer two questions: “is it valid to convert clinical outcomes of
erectile dysfunction into utilities?”, and - serving this question: “is it valid to administer
TTO in groups?”. We have tried to answer these questions in terms of content validity,
criterion validity and construct validity.
Content validity
The analysis of the validity of responses was first of all done on the basis of content
validity: do the responses make sense in terms of absolute value and are they consistent
within the ordinal structure of the 25 health states of erectile dysfunction as defined by
question 3 & 4 of the IIEF. Deviations were expected at the less logical health states like
“almost never being able to penetrate, but always able to maintain the erection after
penetration”.
Criterion validity
The analysis of the validity of the group session was primarily based on the convergence
between the answers recorded in individual measures and in groups. As time trade-off is
usually performed in a face-to-face setting, the individual sessions were seen as the
criterion for the group responses. The analysis was done with a ‘MANOVA repeated
measure’ analysis. The effects are tested both multivariately and univariately. If
statistical significant differences occur, the relevance of the differences was tested in a
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population of patients with erectile dysfunction (baseline data Goldstein, Lue & Padma-
Nathan et al., 1998).
Construct validity
It was recognised that the construct validity of the group sessions would be supported if
the resulting factor structure in the group data would be closely related to the factor
structure of the data of the individual sessions. For instance if the response on question
3 was more important than question 4, during the individual sessions, then this should
also be visible in the data of the group sessions. Introducing question 3 and 4 as two
“within-subjects-factors” in the MANOVA tested the factor structure. A similar factor
structure should result in small or non significant interaction effects between the mode of
administration (individual of group) and the two within-subjects factors (question 3 and
4).
Furthermore it was also expected that the mode of administration would influence the
comprehension of the valuation task. It was therefore expected that more censoring of
data was necessary during the group sessions. Given the complexity of the task, it was
also expected that censoring would be a function of age.
Results
Respondents
A sample of 117 students was recruited, of which 54 were interviewed in groups, and 63
were interviewed individually. In the TTO in groups female students were
overrepresented with 40 females to 14 males. In the individual sessions the man and
female were matched: 32 males and 31 females participated. The mean age for
respondents of TTO in groups was 24 year, the mean age of the respondents of
individual TTO was 22 year (p = 0.000). One of the students discontinued the interview
(individual session) after the health problem ‘erectile dysfunction’ was introduced.
Responses of one of the others students – a male- were excluded (due to criteria B: too
many missings).
We interviewed 169 subjects of the general public. The responses were valid in 148
subjects of the general public (88%). Most exclusion (48%) was based on the second
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criterion: no trade-off for any of the EuroQol states. The mean age of subjects of the
general public with valid responses was 45.5 years (SD 15.2).
Table 2 describes the sample of the general public. The oversampling of male
respondents between 40 and 70 years was not that successful as expected. We hoped
for an over sampling of 100%, but we only succeeded to oversample this group with
about 30%. This resulted in a sample in which the gender distribution is close to the
expected distribution, but the distribution over age is somewhat different from the
distribution in the general population, according to the national statistics.28
Table 2: Representativeness of the sample of the general population with valid responses
Males Females Total Reference
Age group N % N % N % %
18 to 39 24 45.3 29 54.7 53 35.8 42.0
40 to 54 25 55.6 20 44.4 45 30.4 24.0
55 to 70 28 58.3 20 41.7 48 32.4 21.0
71 to 79 1 1 0.70 8.5
>79 0 1 1 0.70 4.0
Total 78 100.0 70 100.0 148 100.0 100.0
Content validity
Figure 1 and table 3 present the mean values of the students (group and individual
sessions combined) and of the general public. Note that the value of the best health
state (no erectile dysfunction) is not measured, but based on theory: 1.00.
Figure 1: Visual representation of the utilities of students and the general public for the 25 erectile dysfunction states defined by IIEF question
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Table 3: Values for three EuroQol states and 28 erectile dysfunction states
Health state General public Students
TTO in groups (N=13) TTO individual (n=57)
Mean SD Mean SD Mean SD
Sig. of the
difference
EuroQol 11211 0.95 0.09 0.94 0.07 0.91 0.10 0.33
11122 0.90 0.11 0.90 0.08 0.87 0.11 0.43
21232 0.68 0.17 0.75 0.11 0.67 0.15 0.08
IIEF q3 IIEF q4
(almost) never Never (almost) 0.74 0.18 0.73 0.14 0.73 0.11 0.71
A few times 0.77 0.18 0.78 0.12 0.76 0.12 0.62
Sometimes 0.79 0.16 0.80 0.13 0.78 0.11 0.27
Most times 0.81 0.17 0.80 0.12 0.81 0.10 0.88
Always (almost) 0.82 0.17 0.80 0.14 0.81 0.10 0.64
A few times Never (almost) 0.79 0.17 0.78 0.13 0.79 0.11 0.73
A few times 0.83 0.16 0.81 0.12 0.82 0.10 0.61
Sometimes 0.85 0.14 0.83 0.10 0.82 0.10 0.53
Most times 0.86 0.15 0.85 0.13 0.86 0.09 0.48
Always (almost) 0.87 0.15 0.86 0.11 0.87 0.08 0.57
Sometimes Never (almost) 0.82 0.17 0.79 0.13 0.82 0.10 0.20
A few times 0.85 0.16 0.82 0.12 0.84 0.09 0.28
Sometimes 0.87 0.14 0.86 0.10 0.85 0.10 0.79
Most times 0.88 0.14 0.86 0.11 0.89 0.08 0.12
Always (almost) 0.91 0.13 0.88 0.10 0.89 0.08 0.54
Most times Never (almost) 0.82 0.15 0.81 0.13 0.85 0.12 0.15
A few times 0.86 0.15 0.84 0.12 0.88 0.08 0.07
Sometimes 0.90 0.13 0.87 0.11 0.90 0.08 0.12
Most times 0.94 0.12 0.91 0.10 0.95 0.06 *0.01
Always (almost) 0.94 0.11 0.93 0.09 0.96 0.05 *0.03
Always (almost) Never (almost) 0.84 0.17 0.83 0.13 0.85 0.11 0.38
A few times 0.88 0.16 0.84 0.14 0.89 0.09 *0.04
Sometimes 0.91 0.13 0.88 0.13 0.91 0.08 0.16
Most times 0.93 0.13 0.93 0.09 0.97 0.05 *0.00
Always (almost) 1.00 1.00 1.00
IIEF q7 Never (almost) 0.75 0.18 0.75 0.16 0.76 0.13 0.90
A few times 0.83 0.16 0.82 0.12 0.83 0.11 0.80
Sometimes 0.88 0.14 0.88 0.09 0.88 0.09 0.91
Most times 0.95 0.11 0.94 0.10 0.96 0.06 0.05
Always (almost) 1.00 1.00 1.00
* Significant (p < .05)
The responses do make sense given their absolute values: health states associated with
erectile dysfunction have a utility below 1.0, but extreme low average values were not
given. The values are also in line with an investigation of the World Health Organization
(WHO). As part of the “Global Burden of Disease Project” a panel of “health workers”
valued erectile dysfunction.29 This panel valued the decrease in quality of life caused by
erectile dysfunction on a utility scale between 12 and 24%.
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The values are consistent with the ordinal structure of the question 3 and 4 of the IIEF.
The expected deviations at the less logical health states are absent. These observations
support the content validity of the valuation process.
Criterion validity
There were no differences in values given by male or female students (p= 0.646). This
was also true in the general public (p = 0.101). Furthermore, age was not related with
the utilities (students: p = 0.225; general public: p = 0.896). This means that it was not
necessary to weight the results for difference in gender and age.
The multivariate analysis shows that there is no main group effect for the mode of
administration: the utilities obtain in the group session were on average the same as in
the individual sessions (p = 0.421). There was however an interaction effect between the
health states and the mode of administration. That means that although there is no
overall effect, there are some health states that were valued differently in a group
session than in an individual session. This is shown in table 3, which presents the
univariate results: 4 relatively good health states are valued higher by the students in the
group session than by the students who where interviewed individually (p < .05). The
relevance of these statistical significant differences is modest. The mean utility of the
follow up data of Goldstein, Lue & Padma-Nathan et al. (1998) increased from .902 to
.914. The mean utility at baseline of this investigation was unaffected, as the differences
occur only in the health states with a relative high utility.
Construct validity
As could be expected from the results above, the mode of administration had a limited,
but significant influence on the factor structure of the valuation space as defined by
question 3 & 4 of the IIEF. The respondents in the group sessions valued the ability to
maintain an erection slightly lower than the subjects in the individual sessions did. In
both the responses from group and the individual sessions it appears that the ability to
penetrate was more important than the ability to maintain an erection.
The amount of invalid responses was minimal both in individual and in group sessions.
Within the general public, exclusion was related to age in the expected direction: half of
the respondents older than 70 years gave invalid responses.
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Discussion
In this investigation we tested the possibility to value the health states defined by a
disease specific questionnaire with TTO. The absolute values showed good content
validity and the results were consistent in terms of the ordinal structure of the
questionnaire. There were no relevant systematic differences in absolute values
between the individual and the group administration. The group sessions did not
increase the amount of invalid data.
In this article we did not analyse in full the differences between the response of the
students and of the general public. Moreover, we also did not fully analyse the
differences in responses related to background variables like the availability of a partner,
having children, sexual activity and sexual satisfaction. These items are evaluated
elsewhere, in combination with the valuation of the IIEF from a patient perspective.20 In
the present article we restricted ourselves to a general introduction into measuring
utilities by disease specific instruments and to the possibilities of group administrations in
order to reduce costs.
The sample of the general public was not completely representative in terms of the
distribution across the age categories and gender. However we did not stratify the
results for this observation, because age and gender did not have a significant influence
on the values of the health states.
There were no relevant systematic differences in absolute values between the individual
and the group administration. There were however some small differences at the level of
the individual health states. These differences account for an 8.3% larger effect of
Viagra using individual data, compared to group data. This means that the in the case of
Viagra the use of group data would give a conservative estimate of the cost-
effectiveness.
One can argue that we only established a validity test of the group sessions in students,
and therefore we are still uncertain about the validity of group session in the general
public. However, we do think that the results of the student investigation can be validly
generalised to the general public for two reasons. First of all, the group sessions in the
general public were not more difficult to administer than in students. A second reason is
that the differences between our group protocol hardly differed from an individual
administration. Comprehension of the valuation task is tested on an individual level, and
as soon as the investigator notes signs of misinterpretation of the task, an intervention at
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an individual level takes place. Note that this remark does not apply to so call “voting
systems” as has been reported in the past30, as these mass administrations hardly allow
for individual interventions.
The IIEF contains more questions than the questions 3, 4 and 7 that were used in this
investigation. In this investigation we combined question 3 and 4 in order to define 25
health states. When a third question would have been added, not 25 but 125 health state
would be defined. This would make it almost impossible to value all health states
empirically. In that case one has to value a sample of these health state, and estimate
the remaining values on the basis of parametric models.31 Because intercourse is
generally seen as the primary endpoint to measure the effect of treatment for erectile
dysfunction, we considered the values for the 25 states defined by question 3 and 4 to
be good estimates of the quality of life effect of erectile dysfunction.
Our results suggest that one can validly value health states of disease specific
questionnaires for the estimation of utilities. This facilitates the use of QALY-analyses. It
would be interesting to test if this approach is consistent with an approach in which
generic classifications systems are used, like the EuroQol and the HUI. Of course this
can only be done if one could expect that these generic questionnaires would validly pick
up the symptoms of the illness. For this reason we could not test the new approach in
that respect, because it was not expected that the EuroQol or the HUI would be sensitive
for erectile dysfunction.
Our results further suggest that one can validly administer TTO in groups. Such group
sessions have been done before24, 25, but a comparison between group and the
standard individual examination has not been reported before.
A specific implication of our research is that we now are able to recalculate the outcomes
of the Viagra trial of Goldstein, Lue & Padma-Nathan et al. (1998) into QALYs. The
resulting cost-effectiveness analysis is described elsewhere in this report.
One of the general implications of our research is that we have proceeded in the
application of QALY-theory: we have demonstrated that it is possible to attribute utilities
to health states as defined by disease specific questionnaires. Furthermore we
demonstrated the validity of a cost-effective group administration of TTO. This enlarges
the area of application of QALY-analysis. It seems even possible to recalculate disease
specific outcomes of trials to QALYs. Furthermore, the enhanced validity of the group
sessions open up the possibility for researcher to quickly assess the utility of different
health states and scenarios, which will facilitate model studies in health sciences.
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Abstract
Introduction
It is anticipated that personal circumstances and the subjective enjoyment of sex
moderate the impact of erectile dysfunction on quality of life. This may not only be true
for patients with erectile dysfunction, but also for the general public, when they judge the
effectiveness of medical interventions which could improve erectile functioning.
Therefore we explored whether the general public can validly attribute values to the
health effects of treatment for erectile dysfunction.
Methods
Twenty eight health states of the International Index of Erectile Function (IIEF) were
valued using time trade-off (TTO) by 106 patient with erectile dysfunction and a
representative sample of 169 individual of the general public. The patients participated in
a phase 4 trial of Viagra.
Results
The results show that both patients and the general public consider the impact on quality
of life of erectile dysfunction to be substantial. The values given by patients were lower
than those of the general public, but the factor structure of the valuation space was the
same. Within the general public, values were not related to age, gender, the availability
of a partner, sexual activity and sexual satisfaction. Only having children seems to be
related to the values given. The factor structure of the valuation space was not
influenced by the background variables mentioned.
Discussion
With the use of the values give in this investigation one can use the IIEF as a utility
measurement which can be used to estimated QALYs. The utility assessment can be
performed from the societal perspective.
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Introduction
One can anticipate that personal circumstances and the subjective enjoyment of sex
moderate the impact of erectile dysfunction on quality of life. This may not only be true
for patients with erectile dysfunction, but also for the general public when valuing the
effects of medical interventions which improve erectile functioning. In this investigation
we assess the impact of background variables on elicited values of both patients and the
general public given to health states of erectile dysfunction, in order to determine whose
values should be used in an economic evaluation of treatments for erectile dysfunction.
In economic evaluation of health care the preferred perspective is the societal.1 Bearing
the costs for an accessible health care system is seen as a societal responsibility.
Consequently, insurance characteristics dominate the financing structure of health care.2
The societal responsibility for an accessible health care system relieves the patient of
the responsibility to  pay the bill; typically, the general public pays most costs. Given that
the general public pays the bulk of the costs in health care, not only patients’
preferences should count when allocating resources in health care, but also the
preferences of the general public which consists of possible future patients. It can even
be argued that the preferences of the general public are more suitable than the
preferences of patients are, because preferences change after the occurrence of a
negative event (such as suffering from a disease). This is not in line with the insurance
characteristics of the health care market. For that reason, health economists have strong
preferences to measure the effects of health care by the values of the general public.3
In health economics the preferences of the general public are preferably measured in
terms of Quality Adjusted Life Years (QALYs).1 In a QALY-analysis a single outcome
measure is created to allow for comparisons across different health care interventions.
Morbidity and mortality are being combined in QALYs by correcting the remaining life
years for the quality of life. This correction factor is often called the ‘utility’ of the health
state. In line with the societal perspective and the insurance principle, this utility
preferably reflects the value that the general public attributes to the quality of life a health
state. Thus, if one wants to make an economic evaluation in terms of QALYs, one has to
know the values of the general public for the health states under examination.
A major drawback in the assessment of the benefits of health care by the general public
is that they lack the experiences of patients. In the societal perspective, the values of the
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general public are only valid when the general public is “well-informed”.3 This may be a
problem when the general public is unaware of the patients suffering from a disease and
subsequently of the consequences of this disease on the quality of life. Erectile
dysfunction may be such disease, given the hidden suffering of the patients. When one
can doubt the awareness within the general public, it may be informative to compare the
values of the general public with values given by the patients. These patients’ values
have a meaning on their own: they represent the values from a “patient perspective”,
also called the “clinical perspective”. As argued before these values differ from societal
values because values of patients do not refer to the costs of treatment. For that reason
patients’ values are not suitable for appraising the effects of health care interventions.
Nevertheless, the patients’ values could be of use in economic appraisal; knowledge
about what constitutes the differences between patients’ values and values of the
general public is building, hence patients’ values could be used to assess the validity of
the values of the general public. Below it is discussed which elements constitute values
for health states.
From an economic point of view and given the insurance principle, the patient is often
characterised as acting according to rational strategies in order to maximise his or her
own benefit. From this perspective it is predicted that patients will find any treatment
worth trying, because they do not bear the costs. Therefore, health economists have
argued that patients’ values suffer from a “strategic bias”: patients will respond in such a
way, that the cost-effectiveness of the intervention would be favourable: “… [The
difference in values between the general public and patients are] … quite consistent with
the action of voluntary health organizations and other special interest groups who seek
to influence governments to expand specific treatment programs.4, page 703 In the
present situation, this would mean that patients would value the health of erectile
dysfunction low, so that the cure would result in a great benefit.
Although this strategic bias is still one of the main motivations for the use values of the
general public, it is nowadays recognised that patients values are perhaps more
influenced by coping or adaptation mechanisms than by strategic motivations.5, 6
Adaptation can be described as a process of interpreting past, present and future
circumstances such that an acceptable level of well-being is achieved.7 In general,
patients tend to value the quality of life of their own health states higher than the general
public. This is most strongly applies to chronic health states; as soon a patient is cured,
the value given to the prior chronic health states (thus retrospectively) drops
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dramatically.8, 9, 10 These lower values can be explained by the loss of the necessity of
the adaptation process to maintain a certain level of emotional well-being. It is likely that
patient populations in a trial will reflect such post-treatment preferences, as soon as they
anticipate an effective solution for their health problem.
Besides strategic bias and adaptation, values for health states are also influenced by
factors related to the subjective way in which health is experienced. Besides making
differences between patients’ values and values of the general public, one can also look
at the possibility that subgroups within the patients or the general public have different
values. If the differences are substantial and meaningful from a policy perspective, Gold,
Patrick & Torrance et al. (1996, page 102) advice to consider different cost-effectiveness
analyses for these subgroups.
The remark above applies to both the patient perspective and the societal perspective.
Different patients groups may have different values. This might for instance also be the
case in erectile dysfunction, given the subjective nature of the enjoyment of sex. Hence,
it may well be that some patients with erectile dysfunction may not experience their
erectile dysfunction as a (big) problem, whereas others do. This might lead to “clinical
selection bias”: because erectile dysfunction has been a taboo subject for a long time,
this suggests that patients who do not find erectile dysfunction a big health problem will
not present themselves to a doctor. Therefore our sample of patients may not be
representative for all patients with erectile dysfunction, as the patients who do not
perceive erectile dysfunction as a problem, will not be present in this or study. It can be
expected that the patients in this investigation will give relatively low values to health
states associated with erectile dysfunction. This clinical selection bias may even be
enhanced if the patients use these preferences to express their motivation to participate
in a clinical trial. For this reason, the values of health states given by patients in clinical
trials, can expected to be lower than the average within the whole patient group.
Within the general public there might also exist subgroups whose values are
systematically different. Expected differences in the values for erectile dysfunction may
occur between groups that differ in general demographic background variables such as
age. For instance it may be expected that older subjects are less interested in sex than
young subjects.11, 12, 13 Another variable may be gender, for two reasons. First of all,
women may have a different attitude towards health states related to sexual functioning.
Secondly, they may have difficulties to imagine the problems associated with erectile
dysfunction. Other background variables that could influence values for erectile
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dysfunction are (for obvious reasons): availability of a partner, having children, sexual
activity and sexual satisfaction.
In order to determine whose values should be used in an economic evaluation of erectile
dysfunction, we applied the theory described above to the values of patients and the
general public for erectile dysfunction. To that end we examined which variables
constitute the values for erectile dysfunction. First we explored the relationship between
the values of patients and the general public for health states of erectile dysfunction. We
expected the values of the patients to be higher when coping mechanisms are dominant.
The values of patients will be lower if: 1) the patients attribute values in a strategic way;
2) the awareness of the problems in the general public is low; or 3) the group of patients
is a specific subgroup of patients for who sex is more important than it is on average in
the general population. Furthermore we explored whether other background variables
such as age, gender, availability of a partner, having children, sexual activity and sexual
satisfaction are related to the value of health states of erectile dysfunction.
Methods
Respondents
We interviewed patients with erectile dysfunction patients and a sample of the general
public to value the health states related to erectile dysfunction.
Patients were recruited in two hospitals that participated in a phase 4 clinical trial of
Viagra: the University Hospital St. Radboud in Nijmegen and the St. Antoniushove
Hospital of Leidschendam. Both hospitals included 75 patients. From a random sample
of the telephone directory we recruited a sample of the general public. The sampling was
based on quota sampling, and stratified on the basis of sex, age and education. In this
process, we especially aimed at recruiting a substantial sample of the men aged 40-70
years, because this group is the target group of health care interventions concerning
erectile dysfunction. The results would be weighted, if 1) substantial difference in gender
and age between the sample and the national statistics occurred, and 2) gender and age
were indeed related to the dependent variable of this investigation, namely the value
attached to health states of erectile dysfunction.
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Respondents of the general public were not notified in advance that the health problem
being examined was erectile dysfunction. Instead the study objective was described as
the valuation of health states. The subjects were invited at the University. They were
paid NLG 30,- (about 14,–  Euro) and got a refund of their travelling expenses.
International Index of Erectile Function
The health state descriptions that had to be valued were based on question 3, 4 and 7 of
the International Index of Erectile Function (IIEF). This is a 15 item questionnaire to
assess sexual functioning.14 Use of this questionnaire is advisable, for several reasons:
it is valid and psychometrically sound, it can be used across different cultures and it
contains the two primary end points of erectile dysfunction treatment as defined by the
National Institutes of Health.15
Figure I: Question 3, 4 and 7 of the IIEF
IIEF Question 3 IIEF Question 4 IIEF Question 7 Response level
During the past 4 weeks, how
often were you able to
penetrate?
During the past 4 weeks, how
often were you able to maintain
the erection?
When you attempted sexual
intercourse, how often was it
satisfactory for you?
Almost never or never Almost never or never Almost never or never 1
A few times A few times A few times 2
Sometimes Sometimes Sometimes 3
Most times Most times Most times 4
Almost always or always Almost always or always Almost always or always 5
The IIEF has been used in the clinical trial in which the efficacy of Viagra was
demonstrated.16 The primary end points in this clinical trial were also question 3 and 4,
thus the same questions as used in this investigation. These items deal with the ability to
penetrate and the ability to maintain the erection after penetration. By addressing the
ability to attain and maintain an erection separately, the IIEF has the sensitivity and
specificity to detect treatment-related changes in patients with erectile dysfunction.14
Because these two primary end points have each five response levels, they define (5 x
5) 25 unique health states (Figure 1). Question 7 is about the satisfaction of the
intercourse in general, without making a direct reference to erectile functioning (figure 2).
The 4 health states as defined by question 7 were valued independently. The subject
valued the total of 28 health states using “time trade-off”. The best health state (no
erectile dysfunction) was not valued, because normal health is a reference point in TTO.
72
Valuation method (TTO)
Time trade-off (TTO) is, next to standard gamble, one of the preferred valuation methods
in health economics that are used to determine the values or “utilities” of health states.
The methodology of this interview technique is described in detail in Drummond, O'Brien
& Stoddart et al. (1997). Based on this standard work, one has to make some
methodological choices to be able to operationalise the method for the specific research
question. These methodological choices are motivated below.
Hypothetical health states
As usual in this kind of valuation tasks, the subjects had to value the health states “for a
person like themselves”. Thus the subjects had to imagine that they had an erectile
dysfunction as described by the 28 health states. That means that older subjects gave
values from an ageing perspective, while persons without a sexual active partner, could
incorporate this circumstance in the values given. The only exception was gender:
women had to imagine that they were men with erectile dysfunction.
The health states of erectile dysfunction were assumed to be chronically. This means
that the subjects had to assume that they were in the health states for the rest of their
lives, other things being equal to their own present and future situation.
The trade-off in time was measured relative to the life expectancy of the subjects. The
subjects had to assume that they would reach their life expectancy in “normal health for
that age”.
Response mode
The health states were presented on cards in random order. Subjects were allowed to
reshuffle the cards. They were also allowed to go back to a former response, if they had
changed their mind during the interview. Because of the large number of states that had
to be valued and because of the intimacy of the subject, it was chosen to let the
respondent record the answers on an answer form instead of letting the interviewer
record the responses. The cards had numbers that corresponded to the answer form.
The answer forms consisted of lines representing the life-span of the respondent. The
respondents indicated on this line the so called “indifference point”. This point indicates
no preference for as much shorter as indicated on the line in full health or living their
complete life span in the health state described on the card. This adaptation of the TTO
administration was based on the work of Bleichrodt & Johannesson.17, 18
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Interview protocol
The interview protocols for the patients and the people of the general public were
designed to be as similar as possible. One of the differences was that the general public
was interviewed during a group session, while the patients were interviewed individually.
Prior to this investigation, the results of group sessions were compared with individual
session. In that investigation, no relevant differences in the values of the health states
were found between the two modes of administration. Details about this investigation are
described in appendix A of this report.19
General instruction concerning valuing health states
Both protocols began with a general introduction after which the subjects practiced TTO
using the health state “sitting in a wheelchair” as an example. During the group sessions,
this health states was valued by a volunteer from the group, and had the form of an
individual administration of TTO, using the “ping-pong interview technique”. After this
example, the group was invited to discuss the results and was encouraged to ask
questions about the procedure if they did not fully understand the task. In both the
individual TTO and the TTO in groups, we tested the ability to perform the task by
valuing 3 generic EuroQol EQ-5D health states (states 11211, 11122 and 21232) with
TTO.20 In both situations the answers were checked and discussed as indicated by the
standard instruction for TTO.1 If there were signs of misinterpretation, the protocol was
explained again. In the groups sessions these checks and additional explanations were
done on an individual basis.
Specific instructions concerning erectile dysfunction
After practicing with the 3 EuroQol EQ-5D states, the members of the general public was
introduced into the health problems associated with erectile dysfunction. This
introduction was skipped in patients. Female subjects of the general public were asked
to put themselves in the position of men, when valuing the problems associated with
erectile dysfunction.
After this introduction, the subjects were asked to value the health states of erectile
dysfunction with the use of TTO. It was explained that some health states may appear
illogical, for instance “almost never being able to penetrated, but always able to maintain
the erection after penetration”. Although these health states may seem odd, patients with
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erectile dysfunction classify themselves in these states.21 Therefore, the subjects were
encouraged to value these states too.
The valuation process
During the validation of the health states of erectile dysfunction, the interviewer checked
the responses. If there were any signs of misinterpretation, the subjects were
interviewed on an individual basis, until the subject could perform the task
independently. For this reason, if there were more than 6 subject in the group session,
the interviewer was assisted with one or two fellow researchers.
Background variables
After the valuation task the members of the general public filled in questions about the
availability of a partner, age, having children, the frequency of intercourse and the
satisfaction of the intercourse in general without making a direct reference to erectile
functioning (question 7 of the IIEF).
Invalid responses
Some subjects did not make any trade-off during the administration of the three EuroQol
health states, even with the worse state (21232). This could mean that they still did not
understand the task. It could also mean that the respondent was a so called
“lexicographic responder”. This means that when a respondent is faced with an option,
he or she will always choose for one particular alternative, no matter how favourable the
other might be. In both cases the responses on time trade-off questions become
meaningless. When the interviewer observed such response, both options were
checked. If the respondent still did not understand the task, the task was explained
again. If the responder seemed to act in a lexicographic way, an even more extreme
health state was proposed. If the subject maintained in his or her lexicographic response
mode, or when it was not feasible to explain the task, the responses of the subject were
excluded. Note that the exclusion of lexicographic responses was only based on the
responses on the EuroQol health states and not on the responses on the health states of
erectile dysfunction. If a respondent did not make any trade-off in case of the health
associated with erectile dysfunction, the responses were judged to be valid, as long as
the subject made a trade-off on the EuroQol states, and it was clear that the respondent
75
understood the task. Responses were also excluded when a respondent traded off more
life years than he or she had left and when the respondent has more than 4 missing
values in the assessment of the 28 health states.
Analysis
Differences between subject groups and background characteristic were tested using
MANOVA repeated measure analyses. In these analyses the differences between
subjects were entered as ‘between subject’ variables.
Besides testing the overall effect, we also examined the interactions of the between
subjects variables and the factor structure of the valuation space as defined by question
3 & 4 of the IIEF. For instance if women found that the response levels of question 3
were more important than those of question 4, then we would check if this preference
also is present in the data of the male subjects. For this purpose, question 3 & 4 were
labelled as two ‘within subjects’ factors in the repeated measure MANOVA. A similar
factor structure should result in small or non-significant interaction effects between the
subgroups and the two ‘within subjects’ factors (question 3 and 4).
Results
Respondents
Of the 150 patients in the clinical trial, 106 were interviewed. Most of the patients who
were not interviewed, had already stopped the phase 4 trial before we were able to
interview them. Most of them stopped because they did not experience a substantial
effect of Viagra. In the 106 interviews, we collected 93 valid responses (88%). Forty of
them were interviewed at the University Hospital St. Radboud in Nijmegen and 64 at the
St. Antoniushove Hospital of Leidschendam. The mean age of these patients was 56.71
(SD 11.39) year.
We interviewed 169 subjects of the general public. The responses were valid in 148
subjects of the general public (88%). Most exclusion (48%) was based on the second
criterion: no trade-off for any of the EuroQol states. The mean age of subjects of the
general public with valid responses was 45.52 years (SD 15.24). Age was a predictor of
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the validity of responses: half of the respondents older than 70 years gave invalid
responses.
Table 1 describes the sample of the general public. The oversampling of male
respondents between 40 and 70 years was not as successful as hoped for. We hoped
for an over sampling of 100%, but we only succeeded to oversample this group with
about 30%. This resulted in a sample in which the gender distribution is close to
expected, but the distribution over age is somewhat different from the distribution in the
general population according to the national statistics.22
Table 1: Representativeness of sample of the general population with valid responses
Males Females Total Reference
Age group N % N % N % %
18 to 39 24 45.3 29 54.7 53 35.8 42.0
40 to 54 25 55.6 20 44.4 45 30.4 24.0
55 to 70 28 58.3 20 41.7 48 32.4 21.0
71 to 79 1 1 0.70 8.5
>79 0 1 1 0.70 4.0
Total 78 100.0 70 100.0 148 100.0 100.0
Differences between patients’ values and values of the general public
Both patients and the general public considered erectile dysfunction to have a
substantial effect on quality of life. For the 24 erectile dysfunction states defined by IIEF
question 3 and 4, the values of the public range from 0.74 to 0.93, while values of
patients range from 0.68 to 0.91 (see Table 2). The mean difference between patients’
values and values of the general public is 0.06 (p < .000). The values for question 7
range from 0.75 to 0.95 in the general public and from 0.68 to 0.91 in patients.
The repeated measure analysis showed that both patients’ values and values of the
general public had the same factor structure given the valuation space as defined by
question 3 & 4 of the IIEF (p ³ 0.10) . That is to say, there was no significant interaction
between the ‘within subjects’ variables (question 3 & 4) and the ‘between subjects’
variables (patients versus general public).
In the general public, all but one of the main effects and interactions effects showed a
statistical significant relation with the values given to health states of erectile dysfunction.
The exception was that subjects with children gave higher values to the health states ( p
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= 0.009). In other words: subjects with children considered erectile dysfunction less a
problem than subjects without children did.
Table 2: Values of patients and the general public for erectile dysfunction
The International Index of Erectile Function (IEFF) General public (N=123) Patients (N=93)
Question 3 question 4 Mean SD Mean SD
never never 0.74 0.18 0.68 0.26
a few times 0.77 0.17 0.70 0.26
Sometimes 0.79 0.16 0.71 0.25
most times 0.80 0.16 0.73 0.24
Always 0.82 0.16 0.74 0.25
a few times never 0.80 0.16 0.73 0.25
a few times 0.83 0.15 0.76 0.24
Sometimes 0.85 0.13 0.78 0.22
most times 0.86 0.14 0.80 0.23
Always 0.87 0.14 0.81 0.22
Sometimes never 0.81 0.15 0.75 0.22
a few times 0.85 0.16 0.79 0.22
Sometimes 0.86 0.14 0.81 0.23
most times 0.88 0.14 0.85 0.21
Always 0.91 0.13 0.85 0.18
most times never 0.82 0.15 0.77 0.24
a few times 0.86 0.15 0.81 0.22
Sometimes 0.90 0.13 0.84 0.19
most times 0.94 0.12 0.91 0.16
Always 0.94 0.12 0.91 0.17
Always never 0.84 0.15 0.79 0.22
a few times 0.89 0.14 0.84 0.20
Sometimes 0.91 0.13 0.87 0.18
most times 0.93 0.13 0.91 0.16
Always 1.00 1.00
IIEF question 7 never 0.75 0.18 0.68 0.25
a few times 0.83 0.16 0.77 0.25
Sometimes 0.88 0.14 0.85 0.20
most times 0.95 0.11 0.91 0.15
Always 1.00 1.00
Discussion
Our results show that both patients and the general public consider erectile dysfunction
to have a substantial impact on quality of life. The values given by patients to health
states of erectile dysfunction were lower than those of the general public, but the factor
structure of the valuation space was the same in patients and the general public. Within
the general public, values were not related to age, gender, the availability of a partner,
sexual activity and sexual satisfaction. Only one background variable seems to have a
relation with the values given: subjects with children gave higher values. The factor
structure of the valuation space was not influenced by the other background variables
mentioned.
With respect to background variables, it is noted that the sample of the general public
was not completely representative in terms of the distribution of age categories. However
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we did not need to stratify the results for this observation, because age did not have
significant influence on the values of the health states. We did not present the influence
of the background variables in patients. Given the homogeneous composition of this
group in terms of the background variables, we did not expect that the power would be
strong enough to detect any influence. We indeed could not detect any significant
relation in the patient population.
We analysed our to determine whether it is possible to use values of the general public
in the utility assessment of erectile dysfunction. The validity of these values could be
doubted, because of the subjective nature of sexual functioning and because of the fact
that the general public might be unaware of the effects that erectile dysfunction has on
quality of life. In order to test the validity we therefore analysed the sensitivity of the
values for background characteristics and we compared the values of the general public
with those of patients. Our results were remarkable.
First of all it was surprising that the values attributed to erectile dysfunction are robust for
the influence of social economic variables. Although these results may have been
anticipated on the basis of the literature3, 24, it is still surprising to see that this also holds
for something as subjective as sexual functioning. After all, these results suggest that
there is a high level of public agreement about the importance of treating erectile
dysfunction. However, the importance of sexual activity has been a taboo subject for a
long time. Can these findings be explained?
A stereotype assumption is that older people are less interested in sex than younger
people. However, this was not observed in the values for the erectile dysfunction. Of
course, it could be that the power of our design was too low to pick up the differences.
However we did pick up the difference between patients and the general public, and the
power was enough to pick up the difference between respondents who had children and
those without. Therefore, our results seem to suggest that the stereotype assumption
about declining interest in sex with age may not be as obvious as anticipated.
Nevertheless, our results seem to be in line with other studies.
Although studies show that sexual activity decreases with age, research also shows that
current physical and social factors play an overriding role in interest in and frequency of
sexual intercourse: having mobility problems was found to be highly correlated to lack of
sexual activity, as was marital status.11, 25 Richardson et al. examine reasons for ending
sexual activity: 30% of the respondents reported lack of a partner. Poor health was cited
by 19 % of both men and women as the reason they ended sexual activity: 15% of the
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men reported inability to perform as a reason. For women the second most reported
reason was lack of interest: 28%.12 In populations older than 60 years, about 60% of the
men are sexually active and 30% of the women.11, 12, 25 Marsiglio et al. show that in a
population of 76 years and over, 26% is sexually active.13
We also expected differences in values of men and women. Remarkably was the finding
that women seemed to use the same value system as the male subjects did. This could
be explained because we explicitly asked the female subjects picture themselves as
men, and to value the health states of erectile dysfunction from that perspective. An
alternative explanation for our findings could be that women are well aware of the value
system of men, and they are capable to respond like men when asked to. It could also
mean that men and women have the same value system for sexual functioning.
Furthermore, we expected that characteristics about someone’s sexual engagements
would influence his or her values for erectile dysfunction. We expected that the people
would value the health states of erectile dysfunction to be less severe when they had no
partner or when they would not have intercourse or only on rare occasions. We expected
the same for subjects with a low satisfaction of their intercourse. We hypothesised that
the responses of these subject would show signs of adaptation or coping. This would
result in higher values for the health states of erectile dysfunction. Much to our surprise
this assumption could not be confirmed in the data analysis. There may be several
explanations for this observation.
For instance, it could be noted that erectile dysfunction not only disturbs the sexual
relationship with the partner. A man with erectile dysfunction can not achieve any
erection at all, thus the patient is not capable of getting an erection during any sexual
activity, including intercourse, but also caressing, foreplay, masturbation and other
sexual stimulation. Therefore, not only the ability to have sexual intercourse is limited,
but also the ability to be involved in other satisfactory sexual activity. Another
explanation is that people without a sexual active partner anticipate to the time when a
sexual partner will be present. In order words, people have a strong believe that things
will change for the best, and therefore they do not adapt to their illness as patients with
chronic diseases do. It is also possible that erectile dysfunction is seen as a handicap in
getting a partner. Therefore erectile functioning may be even more important for a man
without a partner than for a man who has a long standing relation.
Nevertheless, the fact that erectile dysfunction is considered generally an important
health problem could be found surprising in itself. In this respect, our results could be
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reflecting a social change. Given that the importance of sexual activity has been a taboo
subject and that no non-invasive therapy was available, men did not come out with their
problem. This veiled the magnitude of the problem. The availability of a non-invasive
medicine for erectile dysfunction, could have give cause to this change. The media
attention for Viagra, has made the public aware of the incidence and prevalence of this
problem, which in turn could have made patients less ashamed of their problem.
Another remarkable finding was that the values of the general public were higher than
values of patients. In most research this is the other way around.3 This could mean that
the awareness of the problems of erectile dysfunction in the general public is low.
However, the values found in this investigation are in line with an investigation of the
World Health Organization (WHO). As part of the “Global Burden of Disease Project” a
panel of “health workers” valued erectile dysfunction.23 This panel valued the decrease
in quality of life caused by erectile dysfunction on a utility scale between 12 and 24%.
Furthermore, the similar factor structure in values of patients and of the general public
suggest that the general public used the same value system as patients did. This means
that in this case the clinical selection bias and the strategic bias are dominant over
adaptation in the patients’ values. As explained in the introduction, this could be
expected in a situation in which patients participate in a trial with an effective
intervention.
In sum, we conclude that the values of the general public can be validly used in
economic evaluation of treatments for erectile dysfunction. It could be argues that the
general public still is not enough aware of the problems caused by erectile dysfunction,
becvause patient give lower values. However, then the values of the general public will
give a conservative estimate of health care interventions in patients with erectile
dysfunction.
An important implication of this study is that we can use the IIEF as a utility
measurement for the assessment of intervention in erectile dysfunction, based on the
values given in table 2. These utilities can be used to estimate QALYs. When the values
of the general public are used, these QALY-analyses will be ideal for the use in
economic appraisal of health care interventions. When the values of the patients are
used, the utilities are suitable for clinical decision analysis. Note that the values of
question 7 can also be used for interventions which involve other aspects of sexual
functioning than erectile dysfunction. The values could even be used for health care
interventions exclusive for women.
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